Endothelin and the Cardiovascular System: The Long Journey and Where We Are Going

Andreas Haryono 1,2, Risa Ramadhiani 2, Gusty Rizky Teguh Ryanto 2 and Noriaki Emoto 1,2,*

1 Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan; andreasharyono89@gmail.com
2 Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe 658-8558, Japan; helloimrr@gmail.com (R.R.); waniqmatun@gmail.com (G.R.T.R.)
* Correspondence: emoto@kobepharma-u.ac.jp

Simple Summary: In this review, we describe the basic functions of endothelin and related molecules, including their receptors and enzymes. Furthermore, we discuss the important role of endothelin in several cardiovascular diseases, the relevant clinical evidence for targeting the endothelin pathway, and the scope of endothelin-targeting treatments in the future. We highlight the present uses of endothelin receptor antagonists and the advancements in the development of future treatment options, thereby providing an overview of endothelin research over the years and its future scope.

Abstract: Endothelin was first discovered more than 30 years ago as a potent vasoconstrictor. In subsequent years, three isoforms, two canonical receptors, and two converting enzymes were identified, and their basic functions were elucidated by numerous preclinical and clinical studies. Over the years, the endothelin system has been found to be critical in the pathogenesis of several cardiovascular diseases, including hypertension, pulmonary arterial hypertension, heart failure, and coronary artery disease. In this review, we summarize the current knowledge on endothelin and its role in cardiovascular diseases. Furthermore, we discuss how endothelin-targeting therapies, such as endothelin receptor antagonists, have been employed to treat cardiovascular diseases with varying degrees of success. Lastly, we provide a glimpse of what could be in store for endothelin-targeting treatment options for cardiovascular diseases in the future.

Keywords: endothelin; endothelin receptor antagonist; pulmonary hypertension; heart failure; coronary artery disease; hypertension

1. Introduction

The existence of a vasoconstrictor secreted by endothelial cells was first reported by several researchers as early as 1981 [1–4]. This culminates in 1988, where Yanagisawa et al. identified the vasoconstrictor peptide endothelin (ET; now known as endothelin-1 or ET-1) [5]. Endothelin-1 showed potent and long-lasting vasoconstrictor effects on arteries that were never observed with another compound at the time. Not long after the discovery of ET-1, two other isoforms have been discovered, each with distinct functions. These isoforms are known as endothelin-2 [6,7] (ET-2) and endothelin-3 [8] (ET-3). Two G-protein-coupled receptors, endothelin type A (ET A) [9,10] and endothelin type B (ET B) receptors [11,12], which can be activated when bound with endothelin peptides, were also identified. ET-1 and ET-2 are more potent than ET-3 in activating ET A, while all three isoforms are equipotent in activating ET B [13]. Subsequently, two endothelin-converting enzymes (ECEs) that cleaved the endothelin precursor, “big endothelin”, into active peptides were identified (ECE-1 [14,15] and ECE-2 [16]). Since then, researchers have been working to uncover the role of the endothelin system in both health and disease. In this review, we discuss the basic knowledge of endothelin and its role in cardiovascular disease. Evidence of endothelin...
involvement in pathological conditions, both in preclinical and clinical studies, will be presented, and strategies to target this pathway as a therapeutic option in the past, present, and future will be discussed.

2. The Endothelin System

2.1. Biosynthesis of Endothelin

ET-1 belongs to the most abundantly synthesized endothelin peptide family. Mature ET-1 is a 21-amino-acid peptide with two cysteine bridges at the N-terminus and a free hydrophobic C-terminus. The crystal structure of ET-1 was solved recently using X-ray diffraction data collected in 1992 [17,18]. Endothelins have structures similar to snake venom toxins (safarotoxins), whose envenomation causes strong coronary artery constriction [19,20]. Endothelin receptor antagonists have been suggested as antivenoms [21]. Mature ET-1 peptide is synthesized by many types of cells, mainly vascular endothelial and smooth muscle cells, while macrophages, fibroblasts, podocytes, and brain neurons also express it [2,13]. Meanwhile, ET-2 peptide is synthesized mainly by intestinal epithelial cells, while it is also transiently expressed in the lung and ovarian follicles [7,22,23]. Finally, the ET-3 peptide is synthesized by melanocytes, intestinal cells, brain neurons, and other cells [2,24,25]. Endothelin peptide synthesis is activated in response to many factors such as hyperglycemia, hypercholesterolemia, aging, estrogen deficiency, hypoxia, shear stress, microRNAs, and angiotensin II [22–25].

Endothelin biosynthesis involves three steps, as illustrated in Figure 1. Endothelins are initially secreted as precursor 212 amino acid polypeptides, named preproETs. A signal peptidase cleaves the 17-amino acid signal to generate proETs, which are subsequently cleaved at the C and N terminals by furin enzymes to generate big ETs [25,26]. Finally, endothelin-converting enzymes (ECEs) cleave big ETs to produce mature ETs with 21 amino acids [14]. Because big ETs are biologically inactive, this maturation process is their key activity. Interestingly, in mice lacking both ECE-1 and ECE-2, mature endothelin peptide levels were reduced by one-third [27]. Other enzymes such as chymases are involved in the maturation of big ETs [28,29]. The deletion of chymases reduces mature endothelin levels [30,31], whereas overexpression increases it [32,33].

2.2. Endothelin Receptor

To activate its signaling pathways, the endothelin peptides bind to two subtypes of endothelin receptor, the ET_A receptor [9,10] and the ET_B receptor [11,12], which belong to the seven G-protein-coupled transmembrane-spanning domain receptors (GPCRs). Both ET-1 and ET-2 showed equal potency for the ET_A receptor binding, whereas ET-3 showed 100-fold lower affinity for the ET_A receptor. In contrast, ET-1, ET-2, and ET-3 showed similar potency to ET_B receptors [13,34]. ET_A receptor expression was relatively higher in the vascular smooth muscle, whereas ET_B receptor expression was higher in endothelial cells. Thus, ET_A and ET_B receptors are ubiquitously expressed in all organs that receive the blood supply. The ET_A receptor was expressed at the highest level in the lungs and heart, with lower expression in the brain, while the brain and periphery of the lung, such as capillaries, are rich in ET_B receptors [35].

ET_A receptor stimulation induced potent and prolonged vasoconstriction, inflammation, and cell proliferation, whereas ET_B receptor stimulation generally showed the opposite effects (see Figure 2) [34,36]. As such, the ET_B receptor can be considered an ET_A receptor endogenous antagonist. The ET_B receptor also functions in the clearance of ET-1 from circulation (see Figure 2) [37–39]. The crystal structure of the ET_B receptor and its interaction with ligands have been recently determined [40–44]. These findings shed light on the interaction between the ET_B receptor and its ligand as well as the underlying G-protein mechanism.
2.2. Endothelin Receptor

To activate its signaling pathways, the endothelin peptides bind to two subtypes of receptor. Therefore, selective antagonists for these receptors have been identified. Parallelly, the ET-receptor antagonist has been used in experimental studies as a neuroprotective agent.

2.3. Endothelin Agonists and Antagonists

Several compounds can act selectively on endothelin receptors with varying degrees of potency and specificity. BQ123 and FR139317 were the first ET-agonists and antagonists identified. Sarafotoxin 6c, which has been used in experimental studies, is a lower affinity ET-receptor agonist.

ET-1 and ET-3 are rich in ET-capillaries, whereas ET-2 is ubiquitously expressed in all organs that receive blood flow as a neuroprotective agent.

Over the last two decades, the development of selective peptide antagonists to be used in experimental studies has notably increased. IRL1620 and BQ788, which belong to ET-A and ET-B receptors, respectively, have been identified. To date, no ET-2 receptor binding has been established. However, the small crystal structure of the ET-B receptor and its ligand as well as the underlying G protein-coupled receptor characterization and labeling studies have been recently determined.

Figure 1. Biosynthesis of endothelin.

Figure 2. Sites and mechanism of action of endothelin.
2.3. Endothelin Agonists and Antagonists

Numerous peptide and non-peptide compounds that act on endothelin receptors with varying degrees of potency and specificity have been discovered. Some of these compounds act as agonists and antagonists. Several compounds can act selectively, while others are non-selective on endothelin receptors [13]. Over the last two decades, the development of agonists and antagonists for endothelin receptors, ET\(_A\) and ET\(_B\), has been extensively studied. BQ123 and FR139317 were the first ET\(_A\)-selective peptide antagonists to be identified. Parallelly, the ET\(_B\) agonists (BQ3020 and IRL1620) and the first selective antagonist peptide ET\(_B\) (BQ788) were identified. Within five years of the discovery of ET-1, a bioavailable non-peptide antagonist drug of the endothelin system was developed.

ET-1, ET-2, and ET-3 are agonists of the ET\(_A\) and ET\(_B\) receptors. However, because ET-3 has a lower affinity for the ET\(_A\) receptor, it is more likely to activate the ET\(_B\) receptor [45].

To date, no ET\(_A\) receptor agonists, either peptides or non-peptides, have been identified. It is generally accepted that the effects of ET\(_A\) activation in pathophysiological conditions are deleterious; therefore, there is no beneficial evidence for activating the ET-1/ET\(_A\) pathway [46]; however, several ET\(_B\) receptor agonists have been discovered to date. Sarafotoxin 6c, which has been used in experimental studies in humans, has notably high selectivity for rat ET\(_B\) receptors, but less so for human ET\(_B\) receptors [47,48]. IRL1620 [49] and BQ3020 [50] are the most widely used selective ET\(_B\) receptors. IRL1620 is used in experiments involving cerebral blood flow as a neuroprotective agent [51–53] and in cancers [54–56]. BQ3020 has been used in ET\(_B\) receptor characterization and labeling studies [57–59] and as a selective PET agent in vivo [60]. However, there is currently no evidence that agonist agents of endothelin have been initiated in cardiology.

On the contrary, endothelin receptor antagonists (ERAs) have been identified and utilized for several years. ERAs are classified as selective towards one receptor subtype or dual antagonists that block both ET\(_A\) and ET\(_B\) receptors. There is no agreement regarding the classification of these antagonists; however, Davenport and Maguire suggested that selective compounds should have more than 100-fold selectivity towards either ET\(_A\) or ET\(_B\) receptors, while those that display less selectivity than that are defined as balanced antagonists [61]. The clinical evidence of ERA use in cardiovascular diseases will be discussed in a later section.

Bosentan is the first antagonist of both ET\(_A\) and ET\(_B\) receptors and was approved by the U.S. Food and Drug Administration in 2001 for pulmonary arterial hypertension (PAH) [62,63]. The diverse side-effects of bosentan include headache, nasal congestion, flushing, fluid edema, elevated levels of liver enzymes, and anemia, which resemble those of ET\(_A\)-selective antagonists. Bosentan-related elevation of liver enzymes is dose-dependent and typically asymptomatic [13,64–66]. Macitentan is a non-selective endothelin receptor antagonist that was approved for clinical use in PAH in 2013. It was designed by modifying the structure of bosentan to improve its efficacy and tolerability, resulting in reduced side effects, such as lower liver toxicity and lower extremity fluid retention, compared to bosentan [61]. Procitentan is a potent dual ET receptor antagonist derived from macitentan. Aprocitentan is currently under investigation for treatment-resistant hypertension, which will be discussed in detail later [67,68].

The most widely used ET\(_A\) receptor selective antagonist is BQ123 [69] which has been used in both in vivo and in vitro studies. Other peptide-based selective ET\(_A\) receptor antagonists used in experiments were FR139317 [70] and TAK-044 [71]. Ambrisentan [72] and sitaxentan [73] have been used in clinical trials to treat PAH patients. Ambrisentan was the second approved antagonist introduced in clinical settings for PAH treatment in 2007. However, in 2010, sitaxentan was withdrawn owing to cases of idiosyncratic hepatitis resulting in acute liver failure and death [74]. Atrasentan [75], another highly selective ET\(_A\) receptor antagonist, has been successfully used in the treatment of diabetic nephropathy [76].

Selective ET\(_B\) receptor antagonists are less developed compared to other types of endothelin receptor antagonists, attributed to the potential danger of blocking ET-1 clearance and vasodilatation effects [13]. In the pre-clinical setting, the most extensively used ET\(_B\)
The last novel derivative from ERA is the relatively novel agent, sparcentan. Sparcentan is the first orally active antagonist with ET$_A$ receptor and angiotensin II type 1 (AT$_1$) receptor inhibitory activities in a single compound. It was developed by merging the elements present in the irbesartan AT$_1$ receptor antagonists with elements in biphenylsulfonamide ET$_A$ receptors. Currently, sparcentan has been investigated in several clinical trials related to kidney diseases [46,78].

2.4. Genetic Mutations in Endothelin System

Genetic mutations in endothelins, endothelin converting enzymes, and endothelin receptors have been shown to be involved in or risk factors for many diseases. For instance, mutations in endothelin 1 gene are associated with pediatric pulmonary hypertension [79], recessive auriculocondylar syndrome (ACS), and dominant isolated question-mark ears (QME) [80]. The rs9349379 SNP of the PHACTR1 locus (6p24), which is associated with coronary artery disease (CAD), migraine headache, cervical artery dissection, fibromuscular dysplasia, and systemic arterial hypertension [81], is a regulator of endothelin-1 expression [82].

Mutation in the ET$_A$ receptor peptide-binding site alters its subtype selectivity, which affects its interaction with ligands [83]. Mutations in the ET$_A$ receptor cause mandibulofacial dysostosis with alopecia [84]. The genetic variant of EDNRA, rs6841581, is significantly associated with an increased risk of intracranial aneurysm in East Asian populations [85–87]. The ET$_A$ receptor (ENDRA-231 A/G) gene polymorphism is associated with migraine [88,89].

Mutations in endothelin-3 commonly affect the enteric nervous system and the melanocytes. As endothelin-3 exerts its function by interacting with the ET$_B$ receptor, a similar phenomenon occurred in ET$_B$ Receptor mutations. Several mutations in endothelin-3 are associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome) [90–92]. Mutations in the ET$_B$ receptor are also associated with Hirschsprung and Waardenburg syndromes [93–96]. Hypermethylation and downregulation of the ET$_B$ receptor expression are associated with reduced patient survival and poor prognosis in several types of malignancies [97–100].

Not limited to the peptides or receptors only, mutations in the converting enzymes have also been linked to pathological conditions. The R742C mutation in the ECE-1 gene results in a patient with skip lesion Hirschsprung disease, cardiac defects, and autonomic dysfunction [101]. Another variation in ECE-1 is linked to essential hypertension [102].

2.5. Phenotype of Genetic Endothelin Modification in Mice

A whole-body ET-1 knockout mouse was developed by deleting exon 2 of the ET-1 gene [103]. Homozygous deletion (ET-1$^{-/-}$) is lethal in neonates. Caesarian delivered mice on day 18.5, postcoital, all with major craniofacial and cardiac anomalies [103,104]. ET-1$^{-/-}$ mice also have lower neonatal weight, poor thyroid and thymus development, and lesser cardiac sympathetic innervation [105,106]. Heterozygous deletion of ET-1 (ET-1$^{+/-}$) resulted in different phenotypes in which the mice appeared normal, fertile, and with reduced ET-1 concentration in the lung and plasma. However, mice exhibit elevated blood pressure [105]. In the overexpression mouse model (ET-1$^+$), the mice exhibited normal ET-1 in the blood, but increased ET-1 expression in the brain, lungs, and kidneys [107]. These mice exhibited chronic inflammation in the lungs [107]. Kidney phenotypes were more severe, exhibiting increased renal cyst formation, renal interstitial fibrosis, glomerulosclerosis, and age-dependent salt-sensitive hypertension [107–110].

Global ET-2 deletion in mice resulted in severe growth retardation, juvenile lethality, internal starvation, hypothermia, and abnormal lung histology. These findings revealed that ET-2 is important for postnatal growth and survival of mice by regulating energy homeostasis and maintaining lung function [111]. Global ET-2 overexpression in Sprague-Dawley rats, called TGR(hET-2)37, results in male rats having significantly lower body weight accompanied by kidney interstitial and glomerular sclerosis. Female rats exhibit glomerulosclerosis [112,113].
ET-3 heterozygous mice (ET-3+/−) were phenotypically normal. However, global homozygous knockout mice (ET-3−/−) died early postnatally, with an average age of 21 days after birth. The mice also presented with aganglionic megacolon and coat color spotting. This result showed that ET-3 is required for the proper development of enteric neurons derived from the vagal neural crest and epidermal melanocytes derived from the trunk neural crest [114]. Piebaldism (absence of melanocytes in the skin) or lethal spotted (ls) phenotypes arose spontaneously in mouse colonies. These ls/ls mice also presented with megacolon. The ET-3 transgene under the control of human dopamine-β-hydroxylase (DβH) introduced into ls/ls mice reduced piebaldism and megacolon in these mice. This evidence shows that the ls/ls mouse phenotype is a result of ET-3 deficiency [115].

ET-A−/− mice die shortly after birth due to severe craniofacial deformities and neural crest-derived structural abnormalities [116,117]. ET-B+/− mice appeared normal and were able to produce offspring. However, ET-B−/− mice were born healthy but became sick and died within 4 weeks, and showed similar abnormalities as ET-3−/− mice, including megacolon and coat color changes [118]. ECE-1 deletion resulted in mortality between embryonic day 12.5 (E12.5) and 30 min after birth. ECE-1−/− mice showed cardiac and craniofacial anomalies identical to those in ET-1 and ET-A receptor-deficient mice [119]. On the other hand, ECE-2−/− mice survive, appear healthy, fertile, and have the same lifespan as wild-type littermates. The simultaneous deletion of ECE-1 and ECE-2 with ECE-1−/−/ECE-2−/− mice showed broader and more severe cardiac abnormalities than ECE-1−/− mice [27].

3. Endothelin in Cardiovascular Diseases
3.1. Pulmonary Hypertension
3.1.1. Relations between Endothelin and PAH

Pulmonary hypertension (PH) was among the first conditions in which the clinical application of endothelin-targeting agents was tested. PH underwent a change in definition after the World Symposium on Pulmonary Hypertension 2018, where the threshold of the mean pulmonary artery pressure (mPAP) diagnostic criteria decreased from 25 mmHg to 20 mmHg [120]. PH is divided by the WHO into five groups based on etiology (pulmonary arterial hypertension/PAH, PH due to left heart disease, PH due to chronic lung disease or hypoxia, chronic thromboembolic PH/CTEPH, and PH due to other etiologies) [121]. However, a common thread linking the groups, although in varying degrees and locations, is the pulmonary vascular remodeling that causes an increase in pressure. This remodeling process primarily involves the dysfunction of the endothelial cells (EC) and smooth muscle cell (SMC) layers of the vessel, while the contributions of the adventitial layer of the vasculature and other surrounding cells are also noteworthy [122]. These dysfunctions include, but are not limited to, inappropriate vascular tone control, aberrant EC and SMC apoptosis, changes in proliferation capacity of all three vessel layers, and endothelial-to-mesenchymal transition [122,123].

Endothelin is a potent vasoconstrictor expressed in various vascular beds. For example, ET-1 is abundantly expressed in the lung. Due to this, ET is a prime candidate molecule to be involved in PH [34]. Various animal models of pulmonary hypertension have shown that an increase in both the cellular expression and circulating level of ET-1 could be found in chronic hypoxia (3 weeks of 10% O₂), SU5416-hypoxia, and monocrotaline (MCT) models of PH, among others [124–126]. Further studies confirmed the mechanism of action by which endothelin could affect the vascular remodeling and dysfunction [127,128]. In addition to the well-known imbalance of the nitric oxide (NO) and prostacyclin (PGI₂) vasodilation pathways due to the overactivation of ET, other important pathways are also affected by the binding of ET-1 to its receptors, ET-A and ET-B [129].

The expression pattern of ET-A and ET-B receptors in the lung vasculature varies according to the cells, where endothelial cells mainly express ET-B, whereas smooth muscle cells and fibroblasts also express ET-A in addition to ET-B [130,131]. Accordingly, ET-1 affects various processes in these cells, ultimately causing vascular remodeling when overactivated.
As mentioned, impaired balance of vasodilator (NO and PGI) and vasoconstrictors (e.g., thromboxane $A_2$ (TXA2)) due to ET-1 is a major problem in the vasculature, while in smooth muscle cells, aberrant proliferation caused by activation of the PI3K, PLC, and MAPK pathways, in addition to being the effector site of the vasoconstrictive effects, can be observed [2,130]. Not limited to those effects, ET-1 overabundance has also been linked to increased EC apoptosis and decreased SMC apoptosis, the induction of a glycolytic switch in the EC, and the promotion of reactive oxygen species production, among others [132–135]. With a diverse array of pathways capable of being altered by this family of peptides, endothelin becomes vital to tackling the challenge of treating PH.

3.1.2. Clinical Applications of Endothelin and ERAs in PH

With strong evidence of the involvement of endothelin, particularly ET-1, as demonstrated by several preclinical studies, the next important step was to check whether ET played an equally important role in patients. For this purpose, several studies were conducted, with results indicating an increase in ET-1 expression levels in the vascular endothelial cells of PAH patients and in the circulating levels of ET-1 in the blood [136,137]. Furthermore, it was found that the increased presence of ET-1 was not limited to PAH. Reports of ET-1 overabundance can also be found in PH due to left heart disease, PH due to lung disease, and CTEPH [138–140]. This underlines the importance of endothelin regardless of the etiological cause. Consequently, ET-1 has also been explored as a biomarker and especially as a prognostic tool. In patients with PAH, blood ET-1 levels have been shown to have prognostic value in predicting hospitalization and mortality [141].

The most important question regarding endothelin is whether targeting this pathway can translate into a beneficial treatment option. To this end, the blockade of the endothelin receptors ET$\alpha$ and ET$\beta$ through the use of ERA is being tested in clinical trials. Among the groups of PH, PAH is currently the only condition in which the use of ERA is approved [142]. The introduction of ERA helped improve what was previously a bleak prognosis for PAH patients and improved its mortality and morbidity rates. The dual ET$\alpha$/ET$\beta$ receptor antagonist bosentan was first approved as a treatment for PAH in the groundbreaking BREATHE-1 trial published in 2002 [63]. In this trial, 213 patients with primary or connective tissue disease-associated PAH were randomly assigned to either placebo or two different bosentan treatment regimens (125 mg twice daily or 250 mg twice daily) for a minimum of 12 weeks. Here, those treated with bosentan showed promising clinical improvements in the 6 min walk test distance, Borg dyspnea index, WHO functional class, and time to clinical worsening with tolerable levels of adverse effects. This study served as a major turning point in the clinical use of ERA, and further studies have confirmed its efficacy and improved upon the original BREATHE-1 trial. Bosentan, as the first dual ERA approved for clinical use, has also been studied in the PAH of various etiologies. For example, bosentan treatment in PAH due to HIV is beneficial, both in the short and long term, where both hemodynamic and clinical improvements can be seen [143,144]. Portopulmonary hypertension is another condition in which bosentan has been found to have similar clinical and hemodynamic benefits [145,146]. Lastly, in the case of PAH due to congenital heart disease (CHD), bosentan has been reported to be effective in patients with Eisenmenger syndrome in the BREATHE-5 trial [147,148].

Other ERAs with differing affinities to the two ET receptors, such as macitentan or ambrisentan, have also gained approval for use in patients with PAH in the last decade. Notably, the SERAPHIN trial analyzing macitentan usage in PAH patients revealed the benefits of this treatment [149]. In this trial, the investigators analyzed the efficacy of macitentan at two different dosages in comparison to placebo (3 mg or 10 mg), and found a decrease in the primary end-point event (death, lung transplantation, prostanoid treatment, atrial septostomy, or worsening PAH) occurrence rate [149]. Furthermore, macitentan was also recently reported to benefit right ventricular function and structure, in addition to improving hemodynamics in the REPAIR study [150].
In the case of ambrisentan, the ARIES set of clinical trials examined whether treatment with ambrisentan (5 mg or 10 mg doses in ARIES-1 and 2.5 mg or 5 mg doses in ARIES-2) compared to placebo could have beneficial effects [151]. The results showed that ambrisentan could effectively improve the clinical worsening of PAH, WHO functional class, Borg dyspnea index, and B-type natriuretic peptide levels. Notably, ambrisentan treatment did not exponentially increase liver enzyme levels by more than three-fold [151]. It is noteworthy that in both macitentan and ambrisentan, as is the case with bosentan, although there was significant hemodynamic and clinical improvement in comparison to placebo after treatment, the change was not significant enough to stop searching for ways to further improve PAH treatment.

The AMBITION trial answered the question of whether ERA could have a beneficial effect when combined with other PAH treatments [152]. In the AMBITION trial, ambrisentan was administered in combination with the PDE-V inhibitor tadalafil, and it was found that combined therapy with ambrisentan and tadalafil successfully reduced the rate of clinical worsening (death, hospitalization, worsening of PAH, disease progression, unsatisfactory response to treatment), while improving the NT-proBNP and 6 min walk test distance [152]. The TRITON trial attempted to determine whether the upfront triple combination therapy of ERA (macitentan), PDE-V-inhibitor (tadalafil), and prostacyclin receptor agonist (selexipag) is more beneficial than dual therapy (macitentan and tadalafil). Although no difference in pulmonary vascular resistance reduction was found between upfront double and triple therapy, an exploratory analysis showed a potential reduction in disease progression, albeit with a small sample size [153]. Obviously, ambrisentan and/or macitentan have also been analyzed for PAH due to various etiological causes, such as HIV, CHD, or hepatopulmonary hypertension, with varying degrees of success or lack thereof, in the case of the MAESTRO study on Eisenmenger syndrome [154–156].

Unfortunately, not all ERAs are suitable for the treatment of PAH. For instance, the trial for sitaxentan was terminated prematurely owing to the high incidence of liver dysfunction in the treatment arm [34,131]. Trials for newer ERAs have also hit a roadblock with slow recruitment, which was mentioned as the reason for the tezosentan trial in PAH conditions being terminated (NCT01077297). In summary, ERA has become an essential part of PAH treatment in the last decade and contributes to the improvement of patient prognosis.

Unfortunately, clinical trials for other forms of PH have not shown similar effectiveness for the use of ERA. Notably, ERAs failed to show sufficient evidence of efficacy in Group 3 PH due to lung disease or hypoxia, where several clinical trials did not achieve satisfactory results [157]. Notably, a single-center trial from the University Hospital Basel, Switzerland, which examined the use of bosentan in severe COPD, failed to show the benefits of additional ERA in both lung and cardiac functions [157]. Several trials analyzing the efficacy of ERAs in PH associated with idiopathic pulmonary fibrosis (IPF) also did not show a positive effect, and one study even observed that the administration of ambrisentan worsened the clinical condition of IPF patients [158,159]. This result is discouraging, especially considering the fact that ET-1 has been found to be a driver of the pro-fibrotic phenotype found in patients with IPF, both in preclinical and translational studies. However, it is noteworthy that the loss of a different endothelin isoform, ET-2, in the lung could worsen the IPF phenotype in a preclinical study [160]. As such, it might be plausible that different strategies are needed to target the endothelin pathway in this particular group of PH.

Another trial examining ERA use, i.e., bosentan in PH due to left heart disease, also failed to improve lung hemodynamics and RV remodeling [161]. Tezosentan similarly did not improve RV function in patients with a history of PH undergoing cardiac surgery [162]. Furthermore, several studies have shown the occurrence of liver injury due to ERA and fluid retention, which further complicates the use of ERA in this particular condition, such as those found in the MELODY-1 study [163]. These two adverse effects can also become major problems in the application of ERA in other cardiovascular conditions, such as hypertension and heart failure, which will also be discussed in another section.
Chronic thromboembolic pulmonary hypertension or CTEPH represents another condition in which ERA could potentially be used. However, to date, ERA has not been accepted as a treatment option for this condition. Even so, evidence of ERA utility in CTEPH has recently started to come to light. In 2008, the BENEFIT study analyzing the use of bosentan concluded that bosentan had a positive effect on hemodynamics, while no effect could be seen in exercise capacity [164]. Importantly, MERIT-1 reported that macitentan has significant clinical and hemodynamic benefits for patients with inoperable CTEPH [165]. Furthermore, recently, a recent multicenter study of macitentan use in CTEPH was terminated due to reasons unrelated to patient safety (the sponsor decided to discontinue the study). However, from the reported data, it appears that macitentan is a promising treatment option for CTEPH, although further studies are required to confirm this [166]. It is notable that a study found that ET\textsubscript{A} expression was markedly increased in the thromboembolic lesions of CTEPH patients who underwent pulmonary endarterectomy (PEA) [167]. Focusing on blocking this receptor rather than using the traditional dual ET\textsubscript{A}/ET\textsubscript{B} receptor blocker might be an interesting solution to treat CTEPH using ERA.

3.2. Systemic Arterial Hypertension

3.2.1. ET in Basic Molecular Mechanism of Systemic Arterial Hypertension

Because of the nature of endothelin, which was originally found in the endothelium and acts as a vasoconstrictor in a delicate balance with other vasoactive peptides, ET is a highly interesting molecule for analysis in systemic arterial hypertension conditions [34]. Molecular mechanisms linking endothelin and systemic arterial hypertension have been discovered over the years. Various animal models of systemic arterial hypertension have shown that ET-1 levels increase during systemic arterial hypertension, while molecularly, as mentioned in the previous section, ET-1 has been shown to affect various pathways related to vascular tone control, such as the renin–angiotensin–aldosterone system (RAAS), nitric oxide (NO), prostacyclin, TXA\textsubscript{2}, cyclic guanosine monophosphate (cGMP)/cyclic adenosine monophosphate (cAMP), and adrenomedullin receptor activity modifying protein (RAMP) pathways [34,131]. Conversely, the loss of ET-1, specifically in vascular endothelial cells, could adversely affect vascular tone maintenance and cause systemic hypotension [168]. Several of the aforementioned pathways are not only known simply as modulators of vascular tone, but they are also known to be involved in endothelial dysfunction and arterial stiffness, i.e., two processes caused by the imbalance of said modulators. Indeed, it is now thought that endothelin has a wide range of effects beyond simple vasoconstriction. ET-1 is known to play a role in arterial stiffening. For instance, ET-1 is found to regulate pulse wave velocity and contribute to widening pulse pressure, while ET-1 has already been known to be closely related to NO production regulation, a major player in arterial stiffness [169,170]. Another study related ET-1 levels with IL-6, a known marker for arterial stiffness [171]. Lastly, ET-1 is also known to contribute to aging, i.e., another factor that contributes to arterial stiffness, in addition to the related oxidative stress pathway [172].

From the point of view of endothelin receptors, there seems to be some variability among the two endothelin receptors, ET\textsubscript{A} and ET\textsubscript{B}, in vascular tone control. Although the role of ET\textsubscript{A} in the vasculature appears to be clearer, the endothelial ET-1/smooth muscle ET\textsubscript{A} axis plays a straightforward balancing role in maintaining the vascular tone through the release of the aforementioned vasoconstrictors, and the role of ET\textsubscript{B} seems to be rather complex [131]. The ET\textsubscript{B} blockade caused an increase in blood pressure; however, ET\textsubscript{B} knockout mice did not develop elevated blood pressure [173,174]. Additionally, ET\textsubscript{B} together with ET\textsubscript{A} in the kidney has been reported to control the sodium retention function of the kidney and, in turn, cause changes in vascular tone [175]. Taken together, these results indicate that the endothelin system is essential for vascular tone control, and its dysfunction logically leads to pathological consequences.
3.2.2. Clinical Implications of Endothelin in Systemic Arterial Hypertension

Clinical studies have also shown an increase in ET-1 levels in patients with systemic arterial hypertension. Elevated levels of ET-1 have been found in patients with salt-sensitive hypertension, moderate-to-severe systemic essential hypertension, hemangiointerithelioma with systemic arterial hypertension, phaeochromocytoma-related systemic arterial hypertension, and kidney disease, among others [2,135]. Furthermore, a single-nucleotide polymorphism in the PHACTR1 gene, which is associated with several vascular diseases, including systemic arterial hypertension and CAD, was found to regulate the expression of ET-1 [82].

Several ERAs have been analyzed for their efficacy in the treatment of systemic arterial hypertension. The first clinical trial analyzing dual ERA bosentan in systemic arterial hypertension yielded positive results with respect to blood pressure reduction; however, several notable adverse effects occurred in the participants, notably liver enzyme elevation and fluid retention, i.e., a recurring theme for ERAs [176]. Trials in treatment darusentan, a moderately ET_A-selective ERA, also showed improvements in blood pressure with differing levels of adverse event occurrence [177]. The relatively high level of adverse events, combined with the availability of other antihypertensive drug classes with good efficacy and fewer adverse effects, has shifted the application of endothelin-targeting drugs to resistant hypertension conditions.

Resistant hypertension, where systemic arterial hypertension persists even after three or more antihypertensive agents, including diuretics, have been administered, is a condition where ERA is currently being investigated. Several agents, especially those with high ET_A selectivity, are currently under clinical trial. Notable among these trials is the DORADO trial, where three different dosages of darusentan (50 mg, 100 mg, or 200 mg) could effectively reduce both seated systolic and diastolic blood pressure by at least 10 mmHg, a larger drop compared to the placebo-treated control [178,179]. However, in the DORADO-AC trial, in which an active treatment control group of guanfacine was included in addition to three different dosages of darusentan and placebo, placebo treatment unexpectedly reduced systolic blood pressure to a level similar to that of darusentan in the initial seated blood pressure measurement [180]. Only after post-hoc analysis using ambulatory blood pressure measurement did darusentan demonstrate its superiority over placebo and guanfacine, and the results of this trial put a halt in darusentan usage for treatment-resistant hypertension. A novel ERA, procitentan, a metabolite of macitentan, is currently undergoing a phase III trial (PRECISION) in resistant hypertension, buoyed by the positive efficacy results in a dose-dependent study and its overall safety profile [67,68]. The results from preclinical and human studies appear promising, with significant changes in blood pressure (BP) observed within 14 days. Aprocitentan enhances the effect of BP lowering by other antihypertensive drugs. In summary, procitentan exhibits protective capabilities in patients with resistant hypertension.

It is also important to note that although it is beyond the scope of this article, the kidney is another vital organ in the regulation of vascular tone, and various ERAs, especially those selectively blocking ET_A, such as atrasentan, have been shown to be capable of treating kidney-disease-related systemic arterial hypertension. The promising results from ET_A-selective atrasentan treatment in diabetic nephropathy patients, as shown in the SONAR trial and sparsentan (a combination of ET_A-selective ERA and angiotensin II type 1 receptor antagonist) treatment for focal segmental glomerulosclerosis (FSGS) in the DUET trial, suggests that kidney-disease-related systemic arterial hypertension could also be an area where ERA and other endothelin-targeting treatments could be beneficial in the near future [76,181].

3.3. Heart Failure
3.3.1. Endothelin and Heart Failure (HF)

Heart failure due to various etiological causes has long become a topic of interest in relation to endothelin, as it was later shown in various studies that the effects of endothelin do not stop merely at vasoconstriction. Indeed, due to the wide range of molecular and
cellular effects that could be mediated by the binding of ET to its canonical receptor, several molecular pathways are important to cardiomyocyte hypertrophy and heart remodeling, such as phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/glycogen synthase kinase 3 beta (GSK3β), mitogen-activated protein kinase (MAPK) 1/2, transforming growth factor beta (TGF-β), nuclear factor kappa B (NFκB), caspases, natriuretic peptides, and protein kinase C (PKC), among other pathways [182–186].

Of note, as previously mentioned, several pathways and process have been heavily connected with the endothelin system, especially in relation to the development and progression of chronic HF. The renin–angiotensin–aldosterone system has long been identified as a target pathway affected by endothelin activation. Indeed, different changes in ET-1-induced RAAS activation occur during the initial development of chronic HF, where the ET-1/ET_A axis increased blood pressure and induced RAAS downregulation attenuated by the sympathetic nervous system, and during the progression of HF, where RAAS activation could be induced by the same ET-1/ET_A axis due to the cardiac output decrease [187,188]. Another pathway related to endothelin that is important in the progression of HF is the TGF-β, which has been shown to mediate the fibrotic remodeling of the cardiomyocyte [183]. Inflammatory pathways are also another vital part of endothelin-induced factor causing progression of chronic HF. Inflammatory cytokines (e.g., TNF-α, interferon-γ, IL-1β, IL-6) are overproduced in the presence of ET-1 overexpression via NFκB translocation and induction of target cytokines expression, all of which leads to inflammatory cells infiltration and dilated cardiomyopathy phenotype in mice [189]. These are just some of the examples demonstrating the wide range of influence that the endothelin system could have on chronic HF development. The role of endothelin on various etiological causes of chronic HF has been extensively studied throughout the years in various experimental models of HF. Notably, diabetic cardiomyopathy has gained significant interest as a condition in which endothelin plays a significant role. Widyanarto et al., using a streptozotocin mouse model, previously demonstrated that ET-1 is important in the endothelial-to-mesenchymal transition process, which is important in the pathology of diabetic cardiomyopathy [183]. Hypertrophic cardiomyopathy is another condition where ET-1 is known to play a role in inducing its pathological phenotypes. Induced pluripotent stem cell (iPSC)-derived cardiomyocytes isolated from hypertrophic cardiomyopathy treated with ET-1 showed marked hypertrophy and myofibrillar disarray [190]. In addition, pressure overload mouse models due to transverse aortic constriction (TAC) have also shown that ET-1, especially those originating from the vasculature, play an important role in hypertensive myocardial hypertrophy [191]. The development of pacing-induced chronic HF model in dogs is another process where the ET-1/ECE-1/ET_A axis has been proven to be important. Two different studies showed that chronic treatment with ET_A antagonist or with ECE inhibitor could ameliorate the HF phenotype [192,193]. Chronic HF due to ischemic heart disease has been well documented to relate heavily with ET-1 overexpression, such as those found in the failing hearts of rats after prolonged coronary artery ligation, while prolonged treatment with ERAs that selectively target ET_A was reported to improve this condition [194,195]. Changes in both the peptide and in the receptors also occur in ischemic heart-disease-related chronic HF. An increase in ET_A and ET_B receptor expression in the coronary arteries was also observed in ischemic heart disease-caused chronic HF, and in another study, the chronic blockade of these receptors could attenuate left ventricular dysfunction and dilation in rats, which, in part, became the basis of the following clinical trials of ERA on chronic HF condition [196].

In short, the link between all etiological causes of HF is that endothelin, specifically ET-1, plays an important role in heart remodeling through the modulation of inflammation, apoptosis, and fibrosis [197].

3.3.2. Clinical Evidence of Endothelin in Chronic and Acute Heart Failure

As a biomarker, blood ET-1 levels, including the active and modified forms of ET-1, have prognostic value in predicting hospitalization and mortality for both heart failure
with reduced and preserved ejection fractions [198,199]. Similar to other cardiovascular conditions, ET-1 levels are elevated in the blood samples of chronic HF patients of various etiologies, including diabetic cardiomyopathy and hypertrophic cardiomyopathy [200,201]. One study related natriuresis, fluid congestion, and poor clinical prognosis to the elevation of plasma ET-1 levels, while another indicated that a higher ET-1 plasma level at admission is a prognostic marker for poor short-term prognosis in acute heart failure (HF) [202,203]. Chronic HF due to ischemic heart disease has also been correlated clinically with ET-1. The correlation between ET-1 levels and inflammation has also been established in clinical setting. For instance, a study established ET-1, in addition to adrenomedullin, to be correlated to inflammation in chronic HF condition [204]. Additionally, it has also been found that ET-1 levels is elevated together with other inflammatory cytokines (TNF-α, IL-6, and MCP-1) in the macrophages of chronic HF patients [205]. Other inflammatory markers important in chronic HF, such as the C-reactive protein (CRP) and NLRP3, have also been correlated with ET-1 [206–209]. As inflammation has been established as an important pathway that modulates the pathophysiology of chronic HF, the link between endothelin and inflammation becomes essential in devising ways to target endothelin dysfunction as a therapy [208]. All of the evidences above show that ET-1 elevation is an established marker for pathological conditions such as chronic HF.

Unfortunately, clinical trials of ERAs in this condition have either not found satisfactory positive results or were halted prior to achieving the endpoint due to the high occurrence of side effects. Unlike PH and hypertension, although the importance of endothelin in the pathophysiology of various etiological causes of HF both in chronic and acute setting is undeniable, ERA in HF does not enjoy a similar level of clinical success and is currently, in essence, not favored by other drugs targeting different pathways. One of the earliest reported trial for ERA usage in chronic HF condition, The REACH-1 trial, which first analyzed the use of bosentan in chronic HF, was discontinued because of the high occurrence of elevated liver enzyme levels [210]. Similarly, the ENABLE trial that utilized a lower bosentan dosage was halted because of the fluid retention caused by bosentan, a paradoxical effect that is not beneficial for the patients [211]. Other ERAs, such as darusentan in the EARTH trial and enrasentan in the ENCOR trial, did not achieve positive results for ERA treatment in chronic HF [2,212]. Furthermore, recent results from the SONAR trial revealed similar fluid retention problems in atrasentan; however, in a post-hoc analysis, the kidney protection benefit was deemed to outweigh the fluid retention problem [213].

Acute heart failure (acute HF) is another focus of study for the clinical use of ERA. However, similar to chronic conditions, no encouraging results have emerged in this field. The RITZ-1 and RITZ-2 sets of clinical trials attempted to answer the question of whether ERA, in this case the non-selective tezosentan, could be useful in an acute HF setting. Conflicting efficacy results were obtained between RITZ-1, which found no impact of tezosentan on clinical symptoms and cardiovascular events, and RITZ-2, which showed hemodynamic and symptom improvements after tezosentan in severe chronic HF [214,215]. This conflicting result was one of the main reasons for the shelving of tezosentan as a medication for heart failure. Similarly, the VERITAS trial observed minimal clinical effects of tezosentan treatment in acute HF [216]. The discrepancy seen between the successful preclinical studies and disappointing clinical trials could be factored by various causes. These include the administration of other standard-of-care HF treatment in conjunction with ERA treatment in patients that might have overlapping beneficial effect with ERA—a phenomenon that obviously cannot be found in the animal models that only received ERA. Another possible explanation is that the differences in ERA treatment effects (and side effects) between humans and rodents or other animals used as experimental models were physiologically significant enough to elicit unwanted side effects in other untargeted organs only in humans. As such, novel modes of therapy are needed to properly address the need to alter the effects of endothelin on HF. Encouragingly, several clinical studies are being conducted to analyze the perceived “gap” in endothelin importance in HF pathophysiology.
and the ineffectiveness of ERA (NCT 02319590, NCT02124824), with the hope that novel strategies can be implemented to counter the dysfunction of endothelin system in HF. At the same time, treating the phenomenon that is associated with endothelin system activation, such as targeting the inflammation of interleukins, could be beneficial as an alternative.

3.4. Atherosclerosis, Acute Coronary Syndrome and Coronary Artery Disease

3.4.1. Endothelin and Coronary Artery Pathologies

Endothelin has also been implicated in the pathophysiology of atherosclerosis and other CAD, including, but not limited to, vasospastic angina, microvascular angina, prinzmetal angina, and Takotsubo syndrome [2,217–219]. Specifically pertaining to atherosclerosis, the relation of the classical risk factors to develop atherosclerosis (diabetes, obesity, smoking, arterial hypertension) with an increased level of endothelin, specifically ET-1, has demonstrated the correlation between ET-1 and atherosclerosis [220]. ET-1 is also found with increased expression at various sites and cells of atheroma plaques, such as in fresh coronary thrombi of patients with ST-segment elevation myocardial infarction (STEMI) and vascular smooth muscle cells of atherosclerotic coronary arteries [217,221]. The ischemia–reperfusion injury mice model via coronary artery ligation and reperfusion also revealed an increase in plasma ET-1 levels after injury, while the blockade of ET$_A$ could attenuate the myocardial injury via NO-related mechanism [222]. More recently, the ERA tezosentan was also found to be effective in attenuating ischemia–reperfusion-induced left ventricular remodeling in rats [223].

Endothelin also plays a role in immune cells and immunological processes that correlate with the formation of atherosclerotic plaques. ET-1 is known to be pro-inflammatory because of its ability to activate macrophages and release inflammatory cytokines, including TNF-$\alpha$, IL-6, and IL-1$\beta$, while also increasing adhesion molecule expression and stimulating neutrophil aggregation [224]. These effects actually cause a reciprocal induction of ET-1, specifically from the pro-inflammatory cytokines, causing a vicious inflammatory cycle that promotes further vascular injury, thereby promoting atherosclerosis [217,225]. This was confirmed in an in vivo model of high-fat diet-induced atherosclerotic ApoE knockout mice, where overexpression of endothelin ET-1 led to the exacerbation of atherosclerotic lesions and, concurrently, an inflammatory phenotype [226]. This inflammatory phenotype also extends in the event of acute myocardial infarction. As inflammatory cytokines and inflammasomes, such as IL-6, IL-1$\beta$, or NLRP3, has been established to be major players in the condition of acute myocardial infarction, and ET-1, as has been mentioned previously, correlates strongly with inflammation, both as an inducer of cytokine expression and as one of the secreted factors after exposure to inflammation [208,227].

During the formation of the atherosclerotic plaque or during the infarction event, endothelin also plays a role in the post-infarction process of left ventricular repair and remodeling. In relation to the previously mentioned chronic HF due to myocardial injury, there is also evidence of endothelin involvement in the acute post-infarction phase of myocardial remodeling. Specifically, it is implied in the EPHEUS study that an elevation of bigET-1 could be found in the post-infarcted heart [228]. In the animal model, it has already been known that ET-1 levels in the early days of post-infarction correlate with left ventricular remodeling. Interestingly, while the blockade of ET receptors could prove beneficial to attenuate left ventricular remodeling and improve its function post-infarction, as previously mentioned, another study showed that the very early blockade of the same receptors could paradoxically aggravates left ventricular remodeling, implying the importance of endothelin system activation in the acute post-infarction response of the heart [196,229]. Molecularly, some of the molecular pathways previously mentioned in other sections of this review, such as NO, RAAS, and inflammatory pathways, among others, are both important and closely related to endothelin system activity, particularly to ET-1 [230–232]. As such, it is clear that endothelin has also been extensively studied in the field of CAD and it is an important pathway to tackle this condition.
3.4.2. Clinical Application of Endothelin in Coronary Artery Disease

In the clinical setting, many studies have found a correlation between ET-1 and CAD and atherosclerosis [221]. A recent study found that high ET-1 levels are increased in atherosclerotic arteries and could reflect the severity of three-vessel disease [233]. Similarly, another study found that big ET-1 levels were increased in patients with CAD [234]. Furthermore, in patients undergoing CAGB, ET-1 is known to be elevated in patients with diabetes compared with non-diabetic patients [235]. Meanwhile, a clinical trial evaluating eplerenone (EPHESUS), which is known to have anti-inflammatory capability, found that blood levels of bigET-1 could also be reduced by eplerenone treatment [228]. The role of ET-1 in left ventricular remodeling post-infarction is also confirmed by the elevation of its plasma level in the acute post-myocardial infarction phase of patients with acute myocardial infarction [236]. In addition to the peptide, its enzyme, ECE-1, is also found to increase in various cells in atherosclerotic plaques, including endothelial cells, smooth muscle cells, macrophages, and the fibrous cap of the plaque, while this increase in ECE-1 is thought to be functionally relevant [237, 238]. Interestingly, there are different effects of the dual ET receptor blockade and the ET\(_A\)-specific blockade in the peripheral and coronary arteries. In contrast, in the peripheral arteries (in the case of the study conducted by Rafnsson et al.), forearm vasodilation could be best achieved by the dual ET receptor blockade; in coronary arteries, the ET\(_A\)-specific blockade interestingly showed the most effective vasodilation [239, 240]. This can, in part, explain the varying degrees of success ERA has in CAD.

Clinical trials involving ERAs in CAD include ENDORA, whereby ambrisentan treatment in NSTEMI/ACS could reduce neutrophil overactivation and hs-troponin-T levels [241]. In contrast, no effects of ERA were found in acute coronary syndrome accompanying HF, as shown by the RITZ series of trials mentioned above. In the RITZ-4 trial, the investigators focused on the use of tezosentan in the case of acute coronary syndrome-related acute heart failure [242]. Unfortunately, no apparent benefit could be found after tezosentan in comparison with placebo, and this trial dims the hope of tezosentan usage in acute coronary syndrome. Taken together with the results of the studies of ERA in HF, although it is unfortunate that the potential of endothelin as a treatable pathway has not been fully realized, it is encouraging to observe that there are specific groups of patients that could benefit from ERA treatment. Furthermore, recent advances in anti-inflammatory therapy, such as the interleukin-targeting canakinumab and anakinra, gives hope that endothelin system dysfunction could be treated through the alleviation of inflammatory phenotype [208]. Even so, further studies are still warranted to analyze the specific populations that benefit from ERA treatment in addition to devising new strategies to combat the dysfunction of this pathway.

3.5. Others

3.5.1. Cardiac Arrhythmia

Although less evidence can be seen in comparison with other conditions, endothelin also appears to play a role in several arrhythmias. The ET-1/ET\(_A\) axis has been shown to possess arrhythmogenic potential in various studies of cardiomyocytes through several proposed mechanisms, such as its ability to handle intracellular Ca\(^{2+}\) and MMP9-derived pro-fibrotic activity [243, 244]. Atrial fibrillation, for instance, is a condition in which ET-1 and its precursor big ET-1 were found to be elevated, while the arrhythmogenic activity of the pulmonary veins could also be controlled by ET-1 [245-247]. In the case of ventricular arrhythmia, ET-1 gene polymorphism has been identified as a risk factor in having a worse hemodynamic outcome during a ventricular arrhythmia episode [248]. On the contrary, a study in isolated rat cardiomyocytes could not prove that ET-1 has a direct role in causing the arrhythmogenic properties in the ventricle [249]. In short, arrhythmia is a pathological condition where endothelin could be intervened and studied in the future.
3.5.2. Antiangiogenic Treatment Adverse Effects

Antiangiogenic drugs, such as vascular endothelial growth factor (VEGF) inhibitors, have been increasingly used as treatment options to fight several forms of cancer in recent times [250]. One of its adverse events is VEGF inhibition-related hypertension [34,250]. The endothelin system has been previously related to the VEGF pathway, in which the blockade of ET receptors could improve ischemia through the VEGF-NO pathway [251]. Clinically, an increase in ET-1 plasma levels was observed after VEGF inhibition [252]. The ENDEAVOUR trial (NCT 03557190) that analyzed the use of ERA after treatment with VEGF inhibitor has been completed; however, to the best of the authors’ knowledge, no results have been published yet. We hope that endothelin could be a viable alternative to treat this specific inducer of hypertension.

3.5.3. Peripheral Artery Disease

Endothelin has also been found to be involved in the peripheral artery disease development. Of note, in patients with peripheral artery disease, the blood levels of ET-1 are found to increase [253]. In the clinical setting recently, a clinical trial (the CLAU trial) indicated the possible effectiveness of ERA in treating peripheral artery disease [254,255]. In this case, bosentan was administered to patients with intermittent claudication for 12 weeks, and both the initial and four-year follow-up results indicated that bosentan treatment could be effective in improving the claudication distance, C-reactive protein (CRP) levels, and flow-mediated arterial dilation in a select group of patients with low-to-mild stages of PAD with low risk of severe adverse effects [254,255].

4. Future Perspectives

Dysregulation of the endothelin pathway has been identified as a cause of various diseases. Targeting ETA/ETB receptors or their effectors has emerged as the long-term goal of developing new therapies. Over the last few decades, the development of molecular orthosteric and allosteric ligands has been the central focus of endothelin research. Notably, several emerging novel modalities targeting these receptors have been identified, such as pepducins, aptamers, and antibodies.

4.1. Allosteric Modulators

Allosteric modulators are molecules that can alter the biological activity of receptors through distinct binding sites of endogenous ligands. Currently, ET receptor antagonist-related adverse effects have been reported, including the risk of embryonic–fetal toxicity due to the blocking action of ET1. Allosteric modulation that reduces, but does not block, the action of ET1 may offer advantages in this regard [256,257]. The first allosteric modulator was identified in 2000, but there were no allosteric modulators that underwent a clinical trial phase until recently [258,259].

4.2. Peptide-Based Biased ET Receptor Signaling

Recently, in the field of G-protein-coupled receptor (GPCR) research, targeting specific downstream pathways, such as G protein or β-arrestin, via biased orthosteric ligands and/or allosteric modulators, holds a novel paradigm for targeted drug development, as depicted in Figure 3 [260]. This concept has been explored in the cardiovascular field for angiotensin II type 1 receptor (AT1R). The downstream G-protein signaling of AT1R is considered cardio-deleterious, whereas β-arrestin has cardioprotective properties. Targeted novel agonists of AT1R β-arrestin, such as TRV027, have been investigated for heart failure treatment [261,262].

Unfortunately, molecules related to ET-biased signaling have not been explored previously. However, the distinct downstream signaling properties of ET receptors offer a potential explanation for ineffective ET antagonists in cancer treatment, despite numerous studies proving that the endothelin system axis plays a significant role in cancer pathogenesis [263].
Figure 3. Pharmacologic mechanism of biased G-protein-coupled receptor signaling.

4.3. Pepducins/Cell-Penetrating Peptides

Pepducins are synthetic, short, cell-penetrating peptides derived from the three intracellular loops or the C-terminal tail of GPCR and ET_A/ET_B receptors. The N-terminus of pepducins is lipidated to support the transfer process between the cell membrane and anchor the peptide. Once inside the cell, pepducins stabilize receptor conformations, which may stimulate or inhibit intracellular signaling [46,264]. Previous studies have revealed that these pepducins can modulate ET1 signaling capabilities and ameliorate hypoxic-induced pulmonary hypertension in rats [265,266].

4.4. Antibody against ET Receptors

Therapeutic vaccines are novel modalities used for the treatment of chronic diseases, including cardiovascular diseases. Compared with small-molecule drugs, vaccines and antibodies have several advantages. First, the ability of therapeutic antibodies to target antigens is highly specific, resulting in higher efficacy and reduced side effects. Second, the serum half-life of antibodies is relatively high, affecting the frequency of administration and improving patient compliance [267].

Preclinical studies of vaccine-targeting ET_A receptors, getagozumab, have shown promising results for the treatment of hypoxia-induced and monoclonal (MCT)-induced pulmonary arterial hypertension (PAH) in monkey models. Currently, getagozumab is in phase 1b clinical trials [268]. In addition, a monoclonal antibody against ET_A receptors (ETRQβ-002 vaccine/mAb) has been developed to effectively ameliorate pulmonary arterial hypertension (PAH) in MCT-treated and SUGEN–hypoxia-induced animal models, with satisfactory safety properties [269,270]. Similar to ET_A receptors, antibodies targeting ET_B receptors, such as Rendomab-B1 and Rendomab-B4, are also available for cancer treatment, particularly for melanoma [46].

4.5. ET-1 Traps

Endothelin-1 traps or ET traps are molecular constructs composed of molecules that potently bind to ET-1 fused to the Fc portion of human immunoglobulin (Ig)-G1. ET traps have shown potential therapeutic effects in in vitro and diabetic animal models. ET trap administration can have beneficial effects on diabetic target organs, such as the heart and kidney. In addition, ET traps were not immunogenic and did not exhibit any adverse effects. Therefore, the ET trap is an attractive target for further therapeutic development of disease-associated pathological ET-1 [271,272].
5. Conclusions

Endothelin is a vital peptide with three isoforms and was originally identified as a potent vasoconstrictor. In subsequent years, the wide array of influences that the endothelin system can affect has led to evidence that demonstrates the importance of endothelin in various cardiovascular diseases, including hypertension, PH, HF, and CAD, among others. Consequently, strategies have been, and are currently being, developed to improve the ways that clinicians can target this pathway. Although significant progress has been made in the 35 years since the discovery of endothelin, many questions remain in this field, and further studies are encouraged to fully realize the potential of targeting endothelin in cardiovascular diseases.

Author Contributions: Conceptualization, A.H., R.R., G.R.T.R. and N.E.; writing—original draft preparation, A.H., R.R. and G.R.T.R.; writing—review and editing, A.H., R.R., G.R.T.R. and N.E.; supervision, N.E. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by JSPS KAKENHI (Grant Number JP22H02774 to N.E.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Furchgott, R.F.; Vanhoutte, P.M. Endothelium-derived relaxing and contracting factors. *FASEB J.* 1989, 3, 2007–2018. [CrossRef] [PubMed]
2. Barton, M.; Yanagisawa, M. Endothelin: 30 years from discovery to therapy. *Hypertension* 2019, 74, 1232–1265. [CrossRef] [PubMed]
3. Hickey, K.A.; Rubanyi, G.; Paul, R.J.; Highsmith, R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. *Am. J. Physiol. Cell Physiol.* 1985, 17, C550–C556. [CrossRef] [PubMed]
4. O’Brien, R.F.; Robbins, R.J.; McMurtry, I.F. Endothelial cells in culture produce a vasoconstrictor substance. *J. Cell. Physiol.* 1987, 132, 263–270. [CrossRef]
5. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 1988, 332, 411–415. [CrossRef]
6. Saïda, K.; Mitsui, Y.; Ishida, N. A Novel Peptide, Vasoactive Intestinal Contractor, of a New (Endothelin) Peptide Family: Molecular Cloning, Expression, and Biological Activity. *J. Biol. Chem.* 1989, 264, 14136–14146. [CrossRef] [PubMed]
7. Saïda, K.; Hashimoto, M.; Mitsui, Y.; Ishida, N.; Uchide, T. The Prepro Vasoactive Intestinal Contractor (VIC)/Endothelin-2 Gene (EDN2): Structure, Evolution, Production, and Embryonic Expression. *Genomics* 2000, 64, 51–61. [CrossRef] [PubMed]
8. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyachi, T.; Goto, K.; Masaki, T. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc. Natl. Acad. Sci. USA* 1989, 86, 2863–2867. [CrossRef]
9. Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanishi, S. Cloning and expression of a cDNA encoding an endothelin receptor. *Nature* 1990, 348, 730–732. [CrossRef]
10. Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazakit, H.; Kimura, S.; Goto, K.; Masaki, T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. *Nature* 1990, 348, 732–735. [CrossRef]
11. Sakamoto, A.; Yanagisawa, M.; Sakurai, T.; Takuwa, Y.; Yanagisawa, H.; Masaki, T. Cloning and functional expression of human cDNA for the ETB endothelin receptor. *Biochem. Biophys. Res. Commun.* 1991, 178, 656–663. [CrossRef]
12. Saito, Y.; Mizuno, T.; Itakura, M.; Suzuki, Y.; Ito, T.; Hagiwara, H.; Hirose, S. Primary structure of bovine endothelin ETB receptor and identification of signal peptidase and metal protease cleavage sites. *J. Biol. Chem.* 1991, 266, 23433–23437. [CrossRef]
13. Davenport, A.P.; Hyndman, K.A.; Dhaun, N.; Southan, C.; Kohen, D.E.; Pollock, J.S.; Pollock, D.M.; Webb, D.J.; Maguire, J.J. Endothelin. *Pharmacol. Rev.* 2016, 68, 357–418. [CrossRef] [PubMed]
14. Xu, D.; Emoto, N.; Giaid, A.; Slaughter, C.; Kaw, S.; deWit, D.; Yanagisawa, M. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. *Cell* 1994, 78, 473–485. [CrossRef]
15. Takahashi, M.; Matsushita, Y.; Iijima, Y.; Tanzawa, K. Purification and characterization of endothelin-converting enzyme from rat lung. *J. Biol. Chem.* 1993, 268, 21394–21398. [CrossRef]
16. Emoto, N.; Yanagisawa, M. Endothelin-converting Enzyme-2 Is a Membrane-bound, Phosphoramidon-sensitive Metalloprotease with Acidic pH Optimum (+). *J. Biol. Chem.* 1995, 270, 15262–15268. [CrossRef]
Biology 2022, 11, 779

17. McPherson, A.; Larson, S.B. The X-ray crystal structure of human endothelin 1, a polypeptide hormone regulator of blood pressure. Acta Crystallogr. Sect. F 2019, 75, 47–53. [CrossRef]

18. Stanfield, R.L. Never too late for endothelin. Acta Crystallogr. Sect. F 2019, 75, 45–46. [CrossRef]

19. Kloog, Y.; Ambar, I.; Sokolovsky, M.; Kochva, E.; Wollberg, Z.; Bdolah, A. Sarafotoxin, a Novel Vasoconstrictor Peptide: Phosphonositide Hydrolysis in Rat Heart and Brain. Science 1988, 242, 268–270. [CrossRef]

20. Takasaki, C.; Yanagisawa, M.; Kimura, S.; Goto, K.; Masaki, T. Similarity of endothelin to snake venom toxin. Nature 1988, 335, 303. [CrossRef]

21. Abd-Elsalam, M.A. Bosentan, a selective and more potent antagonist for Atractaspid envenomation than the specific antivenom. Toxicol. 2011, 57, 861–870. [CrossRef] [PubMed]

22. Barton, M. Aging and endothelin: Determinants of disease. Life Sci. 2014, 118, 97–109. [CrossRef] [PubMed]

23. Stow, L.R.; Jacobs, M.E.; Wingo, C.S.; Cain, B.D. Endothelin-1 gene regulation. FASEB J. 2011, 25, 16–28. [CrossRef] [PubMed]

24. von Brandenstein, M.; Richter, C.; Fries, J.W.U. MicroRNAs: Small but amazing, and their association with endothelin. Life Sci. 2012, 91, 475–489. [CrossRef] [PubMed]

25. Houde, M.; Desbiens, L.; D’Orléans-Juste, P. Chapter Five—Endothelin-1: Biosynthesis, Signaling and Vasoreactivity. Adv. Pharmacol. 2016, 77, 143–175. [CrossRef] [PubMed]

26. Denault, J.-B.; Claign, A.; D’Orléans-Juste, P.; Sawamura, T.; Kido, T.; Masaki, T.; Leduc, R. Processing of proendothelin-1 by human furin convertase. FERS Lett. 1995, 362, 276–280. [CrossRef]

27. Yanagisawa, H.; Hammer, R.E.; Richardson, J.A.; Emoto, N.; Williams, S.C.; Takeda, S.; Clouthier, D.E.; Yanagisawa, M. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J. Clin. Invest. 2000, 105, 1373–1382. [CrossRef]

28. Wypij, D.M.; Nichols, J.S.; Novak, P.; Lowell Stacy, D.; Berman, J.; Wiseman, J.S. Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem. Pharmacol. 1992, 43, 845–853. [CrossRef]

29. Maguire, J.; Davenport, A.P. Alternative Pathway to Endothelin-Converting Enzyme for the Synthesis of Endothelin in Human Blood Vessels. J. Cardiovasc. Pharmacol. 2004, 44, S27. [CrossRef]

30. Houde, M.; Desbiens, L.; Schwertani, A.; Pejler, G.; Iglarz, M.; D’Orléans-Juste, P. Endothelin receptor antagonist macitentan or deletion of mouse mast cell protease 4 delays lesion development in atherosclerotic mice. Life Sci. 2016, 159, 71–75. [CrossRef]

31. Houde, M.; Jamain, M.-D.; Labonté, J.; Desbiens, L.; Pejler, G.; Gurish, M.; Takai, S.; D’Orléans-Juste, P. Pivotal Role of Mouse Mast Cell Protease 4 in the Conversion and Pressor Properties of Big-Endothelin-1. J. Pharmacol. Exp. Ther. 2013, 346, 31–37. [CrossRef]

32. Guo, C.; Ju, H.; Leung, D.; Massaeli, H.; Shi, M.; Rabinovitch, M. A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J. Clin. Investig. 2001, 107, 703–715. [CrossRef]

33. Hu, H.; Gros, R.; You, X.; Tsang, S.; Husain, M.; Rabinovitch, M. Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc. Natl. Acad. Sci. USA 2001, 98, 7469–7474. [CrossRef]

34. Dhaun, N.; Webb, D.J. Endothelins in cardiovascular biology and therapeutics. Nat. Rev. Cardiol. 2019, 16, 491–502. [CrossRef]

35. Regard, J.B.; Sato, I.T.; Coughlin, S.R. Anatomical Profiling of G Protein-Coupled Receptor Expression. Cell 2008, 135, 561–571. [CrossRef]

36. Schneider, M.P.; Boesen, E.I.; Pollock, D.M. Contrasting Actions of Endothelin ETA and ETB Receptors in Cardiovascular Disease. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 731–759. [CrossRef]

37. Dupuis, J.; Goresky, C.A.; Fournier, A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETBReceptors. J. Appl. Physiol. 1996, 81, 1510–1515. [CrossRef]

38. Dupuis, J.; Stewart, D.J.; Cernacek, P.; Gosselin, G. Human Pulmonary Circulation Is an Important Site for Both Clearance and Processing of Endothelin-1. Circulation 1996, 94, 1578–1584. [CrossRef]

39. Fukuroda, T.; Fujikawa, T.; Ozaki, S.; Ishikawa, K.; Yano, M.; Nishikibe, M. Clearance of Circulating Endothelin-1 by ETB Receptors in Rats. Biochem. Biophys. Res. Commun. 1994, 199, 1461–1465. [CrossRef]

40. Shihoya, W.; Nishizawa, T.; Okuta, A.; Tani, K.; Dohmae, N.; Fujisaki, Y.; Nureki, O.; Doi, T. Activation mechanism of endothelin ETB receptor by endothelin-1. Nature 2016, 537, 363–368. [CrossRef]

41. Shihoya, W.; Izume, T.; Inoue, A.; Yamashita, K.; Kadjii, F.M.N.; Hirata, K.; Aoki, J.; Nishizawa, T.; Nureki, O. Crystal structures of human ETB receptor provide mechanistic insight into receptor activation and partial activation. Nat. Commun. 2018, 9, 4711. [CrossRef]

42. Shihoya, W.; Nishizawa, T.; Yamashita, K.; Inoue, A.; Hirata, K.; Kadjii, F.M.N.; Okuta, A.; Tani, K.; Aoki, J.; Fujisaki, Y.; et al. X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog. Nat. Struct. Mol. Biol. 2017, 24, 758–764. [CrossRef]

43. Nagiri, C.; Shihoya, W.; Inoue, A.; Kadjii, F.M.N.; Aoki, J.; Nureki, O. Crystal structure of human endothelin ETB receptor in complex with peptide inverse agonist IRL2500. Commun. Biol. 2019, 2, 236. [CrossRef]

44. Izume, T.; Miyauchi, H.; Shihoya, W.; Nureki, O. Crystal structure of human endothelin ETB receptor in complex with sarafotoxin S6b. Biochem. Biophys. Res. Commun. 2020, 528, 383–388. [CrossRef]

45. Haynes, W.G.; Strachan, F.E.; Webb, D.J. Endothelin ETA and ETB Receptors Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo. Circulation 1995, 92, 357–363. [CrossRef]
72. Vatter, H.; Zimmermann, M.; Weyrauch, E.; Lange, B.N.; Setzer, M.; Raabe, A.; Seifert, V. Cerebrovascular Characterization of the Novel Nonpeptide Endothelin-A Receptor Antagonist LU 20875. *Clin. Neuropharmacol.* 2003, 26, 73–83. [CrossRef]

73. Wu, C.; Chan, M.F.; Stavros, F.; Raju, B.; Okun, I.; Mong, S.; Keller, K.M.; Brock, T.; Kogan, T.P.; Dixon, R.A.F. Discovery of TBC11251, A Potent, Long Acting, Orally Active Endothelin Receptor-A Selective Antagonist. *J. Med. Chem.* 1997, 40, 1690–1697. [CrossRef]

74. Don, G.W.; Joseph, F.; Celermajer, D.S.; Corte, T.J. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. *Intern. Med. J.* 2012, 42, 1351–1354. [CrossRef]

75. Jarvis, M.F.; Wessale, J.L.; Zhu, C.Z.; Lynch, J.J.; Dayton, B.D.; Calzadilla, S.V.; Padley, R.J.; Opgenorth, T.J.; Kowaluk, E.A. ABI-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. *Eur. J. Pharmacol.* 2000, 388, 29–35. [CrossRef]

76. Heerspink, H.J.L.; Parving, H.-H.; Andress, D.L.; Bakris, G.; Correa-Rotter, R.; Hou, F.-F.; Kitzman, D.W.; Kohan, D.; Makino, H.; McMurray, J.J.V.; et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. *Lancet* 2019, 393, 1937–1947. [CrossRef]

77. Ishikawa, K.; Ibara, M.; Noguchi, K.; Mase, T.; Mino, N.; Saeki, T.; Fukuroda, T.; Fukami, T.; Ozaki, S.; Nagase, T. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. *Proc. Natl. Acad. Sci. USA* 1994, 91, 4892–4896. [CrossRef]

78. Komers, R.; Diva, U.; Inrig, J.K.; Loewen, A.; Trachtman, H.; Rote, W.E. Study Design of the Phase 3 Sparsentan Versus Irbesartan (SPRINT) Study: A Phase 2 Follow-up in Paediatric Scleroderma. *Kidney Int. Rep.* 2020, 5, 494–502. [CrossRef]

79. Kumar, A.; Choudhury, M.; Batra, S.D.; Sikri, K.; Gupta, A. In vivo assessment of a single adenine mutation in 5′UTR of Endothelin-1 gene in paediatric cases with severe pulmonary hypertension: An observational study. *BMJ Res. Notes* 2021, 14, 194. [CrossRef]

80. Gordon, C.T.; Petit, F.; Kroisel, P.M.; Jakobsen, L.; Zechi-Ceide, R.M.; Oufadem, M.; Bole-Feysot, C.; Pruvost, S.; Masson, C.; Tores, F.; et al. Mutations in Endothelin 1 Cause Recessive Auriculocondylar Syndrome and Dominant Isolated Question-Mark Ears. *Am. J. Hum. Genet.* 2013, 93, 1118–1125. [CrossRef]

81. Kiando, S.R.; Tucker, N.R.; Castro-Vega, L.-J.; Katz, A.; D’Escamard, V.; Tréard, C.; Fraher, D.; Albuissou, J.; Kadian-Dodov, D.; Ye, Z.; et al. PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. *PloS Genet.* 2016, 12, e1006367. [CrossRef]

82. Gupta, R.M.; Hadaya, J.; Trehan, A.; Zekavat, S.M.; Roselli, C.; Klarin, D.; Emdin, C.A.; Hilvering, C.R.E.; Bianchi, V.; Mueller, C.; et al. A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression. *Cell* 2017, 170, 522–533.e15. [CrossRef] [PubMed]

83. Krystek, S.R.; Patel, P.S.; Rose, P.M.; Fisher, S.M.; Kienzle, B.K.; Lach, D.A.; Liu, E.C.; Lynch, J.S.; Novotny, J.; Webb, M.L. Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity. *J. Biol. Chem.* 1994, 269, 12383–12386. [CrossRef]

84. Gordon, C.T.; Weaver, K.N.; Zechi-Ceide, R.M.; Madsen, E.C.; Tavares, A.L.P.; Oufadem, M.; Kurihara, Y.; Adameyko, I.; Picard, A.; Breton, S.; et al. Mutations in the Endothelin Receptor Type A Cause Mandibulofacial Dysostosis with Alopecia. *Am. J. Hum. Genet.* 2015, 96, 519–531. [CrossRef] [PubMed]

85. Low, S.-K.; Takahashi, A.; Cha, P.-C.; Zembutsu, H.; Kamatani, N.; Kubo, M.; Nakamura, Y. Genome-wide association study for intracranial aneurysm in the Japanese population identifies three candidate susceptible loci and a functional genetic variant at EDNRA. *Hum. Mol. Genet.* 2012, 21, 2102–2110. [CrossRef]

86. Yasuno, K.; Bakircioglu, M.; Low, S.-K.; Bilguvar, K.; Gaal, E.; Ruigrok, Y.M.; Niemela, M.; Hata, A.; Bijlenga, P.; Kasuya, H.; et al. Common variant near the endothelin receptor A (EDNRA) gene is associated with intracranial aneurysm risk. *Proc. Natl. Acad. Sci. USA* 2011, 108, 19707–19712. [CrossRef]

87. Hong, E.P.; Kim, B.J.; Jeon, J.P.; Yang, J.S.; Choi, H.J.; Kang, S.H.; Cho, Y.J. Association of Endothelin Receptor Type A with Intracranial Aneurysm in 20,609 East Asians: An Updated Meta-Analysis. *World Neurosurg.* 2019, 130, e804–e814. [CrossRef]

88. Tzourio, C.; El Amrani, M.; Poirier, O.; Nicaud, V.; Bousser, M.-G.; Alperovitch, A. Association between migraine and endothelin type A receptor. *Neurology* 2001, 56, 1273–1277. [CrossRef]

89. Miao, J.; Wang, F.; Fang, Y. Association of 231G>A polymorphism of endothelin type A receptor gene with migraine: A meta-analysis. *J. Neurol. Sci.* 2012, 323, 232–235. [CrossRef]

90. Hofstra, R.M.W.; Osinga, J.; Tan-Sindunata, G.; Wu, Y.; Hamming, E.-J.; Stulp, R.P.; van Renswaaiaj-Arts, C.; Majoer-Krakauer, D.; Angrist, M.; Chakravarti, A.; et al. A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg and Hirschsprung phenotype (Shah-Waardenburg syndrome). *Nat. Genet.* 1996, 12, 445–447. [CrossRef]

91. Edery, P.; Attie, T.; Amiel, J.; Pelet, A.; Eng, C.; Hofstra, R.M.W.; Martelli, H.; Bidaud, C.; Munnich, A.; Lyonnet, S. Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome). *Nat. Genet.* 1996, 12, 442–444. [CrossRef]

92. Pingault, V.; Bondurand, N.; Lemort, N.; Sancandi, M.; Ceccherini, I.; Hugot, J.-P.; Jouk, P.-S.; Goossens, M. A heterozygous endothelin 3 mutation in Waardenburg-Hirschsprung disease: Is there a dosage effect ofEDN3/EDNRB gene mutations on neurocristopathy phenotypes? *J. Med. Genet.* 2001, 38, 205–209. [CrossRef] [PubMed]

93. Auricchio, A.; Casari, G.; Staiano, A.; Ballabio, A. Endothelin-B Receptor Mutations in Patients with Isolated Hirschsprung Disease from a Non-Inbred Population. *Hum. Mol. Genet.* 1995, 4, 351–354. [CrossRef] [PubMed]
94. Fuchs, S.; Amiel, J.; Claudel, S.; Lyonnet, S.; Corvol, P.; Pinet, F. Functional Characterization of Three Mutations of the Endothelin B Receptor Gene in Patients with Hirschsprung’s Disease: Evidence for Selective Loss of Gi Coupling. *Mol. Med.* 2001, 7, 115–124. [CrossRef] [PubMed]

95. Varga, L.; Danis, D.; Drsata, J.; Masindova, I.; Skopkova, M.; Slobodova, Z.; Chrobok, V.; Profant, M.; Gasperiokova, D. Novel variants in EDNRB gene in Waardenburg syndrome type II and SOX10 gene in PCWH syndrome. *Int. J. Pediatr. Otorhinolaryngol.* 2021, 140, 110499. [CrossRef]

96. Puffenberger, E.G.; Hosoda, K.; Washington, S.S.; Nakao, K.; deWit, D.; Yanagisawa, M.; Chakravarti, A. A missense mutation of the endothelin-B receptor gene in multigenic hirschsprung’s disease. *Cell* 1994, 75, 1257–1266. [CrossRef]

97. Wei, F.; Ge, Y.; Li, W.; Wang, X.; Chen, B. Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma. *Thorac. Cancer* 2020, 11, 1885–1890. [CrossRef]

98. Smith, S.L.; Damato, B.E.; Scholes, A.G.M.; Nunn, J.; Field, J.K.; Heighway, J. Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. *Br. J. Cancer* 2002, 87, 1308–1313. [CrossRef]

99. Knight, L.; Gibson, N.; Bujac, S.; Ellison, G.; Growcott, J.; Brooks, N.; Hughes, A.; Xinarionas, G.; Liloglou, T.; Field, J. Hypermethylation of endothelin receptor type B (EDNRB) is a frequent event in non-small cell lung cancer. *Cancer Res.* 2007, 67, 1135.

100. Tanaka, T.; Sho, M.; Takayama, T.; Matsumoto, S.; Migitka, I.; Ito, M.; Hamada, K.; Nakajima, Y. Endothelin B receptor expression correlates with tumour angiogenesis and prognosis in oesophageal squamous cell carcinoma. *Br. J. Cancer* 2014, 110, 1027–1033. [CrossRef]

101. Hofstra, R.M.W.; Valdenaire, O.; Arch, E.; Osinga, J.; Kroes, H.; Löffler, B.-M.; Hamosh, A.; Meijers, C.; Buys, C.H.C.M. A Loss-of-Function Mutation in the Endothelin-Converting Enzyme 1 (ECE-1) Associated with Hirschsprung Disease, Cardiac Defects, and Autonomic Dysfunction. *Am. J. Hum. Genet.* 1999, 64, 304–307. [CrossRef]

102. Funke-Kaiser, H.; Reichenberger, F.; Köpke, K.; Herrmann, S.-M.; Pfeifer, J.; Orzechowski, H.-D.; Zidek, W.; Paul, M.; Brand. E. Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. *Hum. Mol. Genet.* 2003, 12, 423–433. [CrossRef] [PubMed]

103. Kurihara, Y.; Kurihara, H.; Suzuki, H.; Kodama, T.; Maemura, K.; Nagai, R.; Oda, H.; Kuwaki, T.; Cao, W.-H.; Kamada, N.; et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. *Nature* 1994, 368, 703–710. [CrossRef] [PubMed]

104. Kurihara, Y.; Kurihara, H.; Oda, H.; Maemura, K.; Nagai, R.; Ishikawa, T.; Yazaki, Y. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. *J. Clin. Investig.* 1995, 96, 293–300. [CrossRef] [PubMed]

105. Kurihara, Y.; Kurihara, H.; Maemura, K.; Kuwaki, T.; Kumada, M.; Yazaki, Y. Impaired development of the thyroid and thymus in endothelin-1 knockout mice. *J. Cardiovasc. Pharmacol.* 1995, 26 (Suppl. 3), S13-6. [CrossRef]

106. Ieda, M.; Fukuda, K.; Hisaka, Y.; Kawaguchi, H.; Fujita, J.; Shimoda, K.; Takeshita, E.; Okano, H.; Kurihara, Y.; et al. Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. *J. Clin. Investig.* 2004, 113, 876–884. [CrossRef] [PubMed]

107. Hocher, B.; Thöne-Reineke, C.; Rohmeiss, P.; Schmager, F.; Slowinski, T.; Burst, V.; Siegmund, F.; Quertemous, T.; Bauer, C.; Neumayer, H.H.; et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. *J. Clin. Investig.* 1997, 99, 1380–1389. [CrossRef] [PubMed]

108. Hocher, B.; Rohmeiss, P.; Thöne-Reineke, C.; Schwarz, A.; Burst, V.; van der Woude, F.; Bauer, C. The Urinary Apoptosis in Kidneys of Endothelin-1 Transgenic Mice. *J. Cardiovasc. Pharmacol.* 1998, 31, S554–S556. [CrossRef]

109. Kalk, P.; Thöne-Reineke, C.; Schwarz, A.; Godes, M.; Bauer, C.; Pfab, T.; Hocher, B. Renal phenotype of Et-1 transgenic mice is modulated by androgens. *Eur. J. Med. Res.* 2009, 14, 55. [CrossRef]

110. Shindo, T.; Kurihara, H.; Maemura, K.; Kurihara, Y.; Ueda, O.; Suzuki, H.; Kuwaki, T.; Ju, K.-H.; Wang, Y.; Ebihara, A.; et al. Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. *J. Mol. Med.* 2002, 80, 105–116. [CrossRef]

111. Chang, I.; Bramall, A.N.; Baynash, A.G.; Rattner, A.; Rakheja, D.; Post, M.; Joza, S.; McKerlie, C.; Stewart, D.J.; McInnes, R.R.; et al. Endothelin-2 deficiency causes growth retardation, hypothermia, and emphysema in mice. *J. Clin. Investig.* 2013, 123, 2643–2653. [CrossRef]

112. Liefeldt, L.; Schönfelder, G.; Böcker, W.; Hocher, B.; Talsness, C.E.; Rettig, R.; Paul, M. Transgenic rats expressing the human ET-2 gene: A model for the study of endothelin actions in vivo. *J. Mol. Med.* 1999, 77, 565–574. [CrossRef] [PubMed]

113. Hocher, B.; Liefeldt, L.; Thöne-Reineke, C.; Orzechowski, H.-D.; Distler, A.; Bauer, C.; Paul, M. Characterization of the Renal Phenotype of Transgenic Rats Expressing the Human Endothelin-2 Gene. *Hypertension* 1996, 28, 196–201. [CrossRef] [PubMed]

114. Baynash, A.G.; Hosoda, K.; Giaid, A.; Richardson, J.A.; Emoto, N.; Hammer, R.E.; Yanagisawa, M. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. *Cell* 1994, 79, 1277–1285. [CrossRef]

115. Rice, J.; Doggett, B.; Sweetser, D.A.; Yanagisawa, H.; Yanagisawa, M.; Kapur, R.P. Transgenic rescue of aganglionosis and piebaldism in lethal spotted mice. *Dev. Dyn.* 2000, 217, 120–132. [CrossRef]
116. Clouthier, D.E.; Hosoda, K.; Richardson, J.A.; Williams, S.C.; Yanagisawa, H.; Kuwaki, T.; Kumada, M.; Hammer, R.E.; Yanagisawa, M. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. *Development* **1998**, *125*, 813–824. [CrossRef]

117. Yanagisawa, H.; Hammer, R.E.; Richardson, J.A.; Williams, S.C.; Clouthier, D.E.; Yanagisawa, M. Role of Endothelin-1/Endothelin-A receptor-mediated signaling pathway in the aortic arch patterning in mice. *J. Clin. Investig.* **1998**, *102*, 22–33. [CrossRef]

118. Hosoda, K.; Hammer, R.E.; Richardson, J.A.; Yanagisawa, H.; Cheung, J.C.; Giaid, A.; Yanagisawa, M. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megaconl associated with spotted coat color in mice. *Cell* **1994**, *79*, 1267–1276. [CrossRef]

119. Yanagisawa, H.; Yanagisawa, M.; Kapur, R.P.; Richardson, J.A.; Williams, S.C.; Clouthier, D.E.; de Wit, D.; Emoto, N.; Hammer, R.E. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. *Development* **1998**, *125*, 825–836. [CrossRef]

120. Simonneau, G.; Montani, D.; Celermajer, D.S.; Denton, C.P.; Gatzoulis, M.A.; Krowka, M.; Williams, P.G.; Souza, R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur. Respir. J.* **2019**, *53*, 1801913. [CrossRef]

121. Galie, N.; Humbert, M.; Vachiery, J.L.; Gibbs, S.; Lang, I.; Torbicki, A.; Simonneau, G.; Peacock, A.; Vonk Noordegraaf, A.; et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endor. *Eur. Respir. J.* **2015**, *46*, 903–975. [CrossRef]

122. Tudor, R.M. Pulmonary vascular remodeling in pulmonary hypertension. *Cell Tissue Res.* **2017**, *367*, 643–649. [CrossRef] [PubMed]

123. Tudor, R.M.; Archer, S.L.; Dorfmuller, P.; Erzurum, S.C.; Guignabert, C.; Michelakis, E.; Rabinovitch, M.; Schermuly, R.; Stenmark, K.R.; Morrell, N.W. Relevant issues in the pathology and pathobiology of pulmonary hypertension. *J. Am. Coll. Cardiol.* **2014**, *62*, D4–D12. [CrossRef]

124. Miyauchi, T.; Yorikane, R.; Sakai, S.; Sakurai, T.; Okada, M.; Nishikibe, M.; Yano, M.; Yamaguchi, I.; Sugishita, Y.; Goto, K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. *Circ. Res.* **1993**, *73*, 887–897. [CrossRef] [PubMed]

125. Li, H.; Chen, S.J.; Chen, Y.F.; Meng, Q.C.; Durand, J.; Elton, T.S. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. *J. Appl. Physiology* **1994**, *77*, 1451–1459. [CrossRef]

126. Kang, B.-Y.; Park, K.K.; Kleinhenz, J.M.; Murphy, T.C.; Blij, K.M.; Yeligar, S.M.; Carthan, K.A.; Searles, C.D.; et al. Peroxisome Proliferator–Activated Receptor γ and microRNA 98 in Hypoxia-Induced Endothelin-1 Signaling. *Am. J. Respir. Cell Mol. Biol.* **2016**, *54*, 136–146. [CrossRef]

127. Amiri, F.; Virdis, A.; Neves, M.F.; Iglarz, M.; Seidah, N.G.; Touyz, R.M.; Reudelhuber, T.L.; Schiffrin, E.L. Endothelin-Restricted Overexpression of Human Endothelin-1 Causes Vascular Remodeling and Endothelial Dysfunction. *Circulation* **2004**, *110*, 2233–2240. [CrossRef]

128. Lambers, C.; Roth, M.; Zhang, J.; Campregher, C.; Binder, P.; Burian, B.; Petkov, V.; Block, L.-H. The Interaction of Endothelin-1 and TGF-β1 Mediates Vascular Cell Remodeling. *PloS ONE* **2013**, *8*, e73399. [CrossRef]

129. Bourque, S.L.; Davidge, S.T.; Adams, M.A. The interaction between endothelin-1 and nitric oxide in the vasculature: New perspectives. *Am. J. Physiol. Integr. Comp. Physiol.* **2011**, *300*, R1288–R1295. [CrossRef]

130. Galie, N. The endothelin system in pulmonary arterial hypertension. *Cardiaccas. Res.* **2004**, *61*, 227–237. [CrossRef]

131. Miyagawa, K.; Emoto, N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. *Ther. Adv. Cardiovasc. Dis.* **2014**, *8*, 202–216. [CrossRef]

132. Maruyama, H.; Sakai, S.; Dewachter, L.; Dewachter, C.; Rondelet, B.; Naeje, R.; Ieda, M. Endothelin-1 Induces Lysyl Oxidase Expression in Pulmonary Artery Smooth Muscle Cells. *Can. J. Physiol. Pharmacol.* **2020**, *98*, 629–636. [CrossRef] [PubMed]

133. Wedgwood, S.; McMullen, D.M.; Bekker, J.M.; Fineman, J.R.; Black, S.M. Role for Endothelin-1–Induced Superoxide and Peroxynitrite Production in Rebound Pulmonary Vascular Remodeling Associated with Inhaled Nitric Oxide Therapy. *Circ. Res.* **2001**, *89*, 357–364. [CrossRef] [PubMed]

134. Biasin, V.; Chwalek, K.; Wilhelm, J.; Best, J.; Marsh, L.M.; Ghanim, B.; Klepetko, W.; Fink, L.; Schermuly, R.T.; Weissmann, N.; et al. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. *Int. J. Biochem. Cell Biol.* **2014**, *54*, 137–148. [CrossRef] [PubMed]

135. Sun, X.; Kumar, S.; Sharma, S.; Aggarwal, S.; Lu, Q.; Gross, C.; Rafikova, O.; Lee, S.G.; Dasarathy, S.; Hou, Y.; et al. Endothelin-1 Induces a Glycolytic Switch in Pulmonary Arterial Endothelial Cells via the Mitochondrial Translocation of Endothelial Nitric Oxide Synthase. *Am. J. Respir. Cell Mol. Biol.* **2014**, *50*, 1084–1095. [CrossRef] [PubMed]

136. Giaid, A.; Yanagisawa, M.; Langleben, D.; Michel, R.P.; Levy, R.; Shennib, H.; Kimura, S.; Masaki, T.; Duguid, W.P.; Stewart, D.J. Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. *N. Engl. J. Med.* **1993**, *328*, 1732–1739. [CrossRef]

137. Cacoub, P. Endothelin-1 in the lungs of patients with pulmonary hypertension. *Cardiaccas. Res.* **1997**, *33*, 196–200. [CrossRef]

138. Çelik, G.; Karabiyikoglu, G. Local and Peripheral Plasma Endothelin-1 in Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease. *Respiration* **1998**, *65*, 289–294. [CrossRef]

139. Chowdhury, M.A.; Moukarbel, G.Y.; Gupta, R.; Frank, S.M.; Anderson, A.M.; Liu, L.C.; Khouri, S.J. Endothelin 1 Is Associated with Heart Failure Hospitalization and Long-Term Mortality in Patients with Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension. *Cardiology* **2019**, *143*, 124–133. [CrossRef]
165. Ghofrani, H.-A.; Simonneau, G.; D’Arminio, A.M.; Fedullo, P.; Howard, L.S.; Jaïs, X.; Jenkins, D.P.; Jing, Z.-C.; Madani, M.M.; Martin, N.; et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): Results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. *Lancet Respir. Med.* 2017, 5, 785–794. [CrossRef]

166. Sakurai, S.; Ukyo, Y. Results of Macitentan in Japanese Patients with Chronic Thromboembolic Pulmonary Hypertension—A Prospective, Multicenter, Open-Label, Single-Arm, Phase 3 Study. *Circ. Rep.* 2021, 3, CR-21-0034. [CrossRef] [PubMed]

167. Southwood, M.; MacKenzie Ross, R.V.; Kuc, R.E.; Hagan, G.; Sheares, K.K.; Jenkins, D.P.; Goddard, M.; Davenport, A.P.; Pepke-Zaba, J. Endothelin ET A receptors predominate in chronic thromboembolic pulmonary hypertension. *Life Sci.* 2016, 159, 104–110. [CrossRef] [PubMed]

168. Kisanuki, Y.Y.; Emoto, N.; Ohuchi, T.; Widyanarto, B.; Yagi, K.; Nakayama, K.; Kedzierski, R.M.; Hammer, R.E.; Yanagisawa, H.; Williams, S.C.; et al. Low Blood Pressure in Endothelial Cell-Specific Endothelin 1 Knockout Mice. *Hypertension* 2010, 56, 121–128. [CrossRef] [PubMed]

169. McNenry, C.M.; Qaseem, A.; Schmitt, M.; Avolio, A.P.; Cockcroft, J.R.; Wilkinson, I.B. Endothelin-1 regulates arterial pulse wave velocity in vivo. *J. Am. Coll. Cardiol.* 2003, 42, 1975–1981. [CrossRef]

170. Wilkinson, I.B.; Franklin, S.S.; Cockcroft, J.R. Nitric Oxide and the Regulation of Large Artery Stiffness. *Hypertension* 2004, 44, 112–116. [CrossRef]

171. du Plooy, C.S.; Mels, C.M.C.; Huisman, H.W.; Kruger, R. The Association of Endothelin-1 with Markers of Arterial Stiffness in Black South African Women: The SABPA Study. *J. Amino Acids* 2015, 2015, 481517. [CrossRef]

172. Kostov, K. The Causal Relationship between Endothelin-1 and Hypertension: Focusing on Endothelial Dysfunction, Arterial Stiffness, Vascular Remodeling, and Blood Pressure Regulation. *Life Sci.* 2021, 11, 986. [CrossRef] [PubMed]

173. Fryer, R.M.; Rakestraw, P.A.; Banfor, P.N.; Cox, B.F.; Opengenorth, T.J.; Reinhart, G.A. Blood pressure regulation by ET A and ET B receptors in conscious, telemetry-instrumented mice and role of ET A in hypertension produced by selective ET B blockade. *Am. J. Physiol. Circ. Physiol.* 2006, 290, H2554–H2559. [CrossRef] [PubMed]

174. Bagnall, A.J.; Kelland, N.F.; Guliwer-Sloan, F.; Davenport, A.P.; Gray, G.A.; Yanagisawa, M.; Webb, D.J.; Kotelevtsev, Y.V. Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt. *Hypertension* 2006, 48, 286–293. [CrossRef] [PubMed]

175. Boesen, E.; Pollock, D.M. Cooperative role of ET A and ET B receptors in mediating the diuretic response to intramedullary hyperosmotic NaCl infusion. *Am. J. Physiol.* 2010, 299, F1424–F1432. [CrossRef]

176. Krum, H.; Viskoper, R.J.; Lacourciere, Y.; Budde, M.; Charlon, V. The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension. *N. Engl. J. Med.* 1998, 338, 794–791. [CrossRef]

177. Nakov, R.; Pfarr, E.; Eberle, S.; HEAT Investigators. Darusentan: An effective endothelin A receptor antagonist for treatment of hypertension. *Am. J. Hypertens.* 2002, 15, 583–589. [CrossRef]

178. Webb, D.J. DORADO: Opportunity Postponed. *Hypertension* 2010, 56, 806–807. [CrossRef]

179. Weber, M.A.; Black, H.; Bakris, G.; Krum, H.; Linas, S.; Weiss, R.; Linseman, J.V.; Wiens, B.L.; Warren, M.S.; Lindholm, L.H. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. *Lancet* 2009, 374, 1423–1431. [CrossRef]

180. Bakris, G.L.; Lindholm, L.H.; Black, H.R.; Krum, H.; Linas, S.; Linseman, J.V.; Arterburn, S.; Sager, P.; Weber, M. Divergent Results Using Clinic and Ambulatory Blood Pressures. *Hypertension* 2010, 56, 824–830. [CrossRef]

181. Trachtman, H.; Nelson, P.; Adler, S.; Campbell, K.N.; Chaudhuri, A.; Derelah, V.K.; Gambaro, G.; Gesualdo, L.; Gipson, D.S.; Hogan, J.; et al. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sarpentan in Patients with FSGS. *J. Am. Soc. Nephrol.* 2018, 29, 2745–2754. [CrossRef]

182. Nicoletti, A.; Michel, J. Cardiac fibrosis and inflammation: Interaction with hemodynamic and hormonal factors. *Cardiovasc. Res.* 1999, 41, 532–543. [CrossRef]

183. Widyanarto, B.; Emoto, N.; Nakayama, K.; Anggrahini, D.W.; Adiarto, S.; Iwasa, N.; Yagi, K.; Miyagawa, K.; Rikitake, Y.; Suzuki, T.; et al. Endothelial Cell-Derived Endothelin-1 Promotes Cardiac Fibrosis in Diabetic Hearts Through Stimulation of Endothelial-to-Mesenchymal Transition. *Circulation. Physiol.* 2010, 121, 2407–2418. [CrossRef] [PubMed]

184. Shin, A.N.; Dasgupta, C.; Zhang, G.; Seal, K.; Zhang, L. Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation. *Curr. Top. Med. Chem.* 2017, 17, 1788–1802. [CrossRef] [PubMed]

185. Pikkarainen, S.; Tokola, H.; Majalahi-Palviainen, T.; Kerkelä, R.; Hautala, N.; Bhalla, S.S.; Charron, F.; Nemer, M.; Vuolteenaho, O.; Ruskoaho, H. GATA-4 is a nuclear mediator of mechanical stretch-activated hypertrophic program. *J. Biol. Chem.* 2003, 278, 23807–23816. [CrossRef]

186. Thibault, G.; Doubell, A.F.; Garcia, R.; Larivière, R.; Schiffrin, E.L. Endothelin-stimulated secretion of natriuretic peptides by rat atrial myocytes is mediated by endothelin A receptors. *Circ. Res.* 1994, 74, 460–470. [CrossRef]

187. Konstam, M.A.; DeNofrio, D. Endothelin Expression and the Progression of Heart Failure. *Circulation* 2004, 109, 143–145. [CrossRef]

188. Abukar, Y.; May, C.N.; Ramchandra, R. Role of endothelin-1 in mediating changes in cardiac sympathetic nerve activity in heart failure. *Am. J. Physiol. Integr. Comp. Physiol.* 2016, 310, R94–R99. [CrossRef]

189. Yang, L.L.; Gros, R.; Kabir, M.G.; Sadi, A.; Gotlieb, A.I.; Husain, M.; Stewart, D.J. Conditional Cardiac Overexpression of Endothelin-1 Induces Inflammation and Dilated Cardiomyopathy in Mice. *Circulation* 2004, 109, 255–261. [CrossRef]
190. Gu, M.; Shao, N.Y.; Sa, S.; Li, D.; Termglinchan, V.; Ameen, M.; Karakikes, I.; Sosa, G.; Grubert, F.; Lee, J.; et al. Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers. *Cell Stem Cell* 2017, 20, 490–504.e5. [CrossRef]

191. Heiden, S.; Vignon-Zellweger, N.; Masuda, S.; Yagi, K.; Nakayama, K.; Yanagisawa, M.; Emoto, N. Vascular endothelium derived endothelin-1 is required for normal heart function after chronic pressure overload in mice. *PLoS ONE* 2014, 9, e88730. [CrossRef]

192. Borgeson, D.D.; Grantham, J.A.; Williamson, E.E.; Luchter, A.; Redfield, M.M.; Opgenorth, T.J.; Burnett, J.C. Chronic Oral Endothelin Type A Receptor Antagonism in Experimental Heart Failure. *Hypertension* 1998, 31, 766–770. [CrossRef] [PubMed]

193. Wada, A.; Tsutamoto, T.; Ohnishi, M.; Sawaki, M.; Fukai, D.; Maeda, Y.; Kinoshita, M. Effects of a Specific Endothelin-Converting Enzyme Inhibitor on Cardiac, Renal, and Neurohumoral Functions in Congestive Heart Failure. *Circulation* 1999, 99, 570–577. [CrossRef] [PubMed]

194. Tonnessen, T.; Christensen, G.; Oie, E.; Holt, E.; Kjekshus, H.; Smiseth, O.; Sejersted, O.; Attramadal, H. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats. *Cardiovasc. Res.* 1997, 33, 601–610. [CrossRef]

195. Sakai, S.; Miyauchi, T.; Kobayashi, M.; Yamaguchi, I.; Goto, K.; Sugishita, Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. *Nature* 1996, 384, 353–355. [CrossRef]

196. Fraccarollo, D.; Hu, K.; Galuppo, P.; Gaudron, P.; Ertl, G. Chronic Endothelin Receptor Blockade Attenuates Progressive Ventricular Dilatation and Improves Cardiac Function in Rats with Myocardial Infarction. *Circulation* 1997, 96, 3963–3973. [CrossRef]

197. Vignon-zellweger, N.; Heiden, S.; Miyauchi, T.; Emoto, N. Endothelin and endothelin receptors in the renal and cardiovascular systems. *Life Sci.* 2012, 91, 490–500. [CrossRef]

198. Gottlieb, S.S.; Harris, K.; Todd, J.; Estis, J.; Christenson, R.H.; Torres, V.; Whittaker, K.; Rebuck, H.; Wawrzyniak, A.; Krantz, D.S. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. *Clin. Biochem.* 2015, 48, 292–296. [CrossRef]

199. He, X.; Guo, H.; Xu, J. Endothelin 1: A Potential Prognostic Biomarker for Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension? *Cardiology* 2020, 145, 262. [CrossRef]

200. Pek, S.L.T.; Lim, S.C.; Ang, K.; Kwan, F.Y.; Tang, W.E.; Sum, C.F.; Tavintharan, S. Endothelin-1 predicts incident diabetic peripheral neuropathy in Type 2 Diabetes: A cohort study. *Eur. J. Endocrinol.* 2020, 182, 429–438. [CrossRef]

201. Wang, Y.; Tang, Y.; Zou, Y.; Wang, D.; Zhu, L.; Tian, T.; Wang, J.; Bao, J.; Hui, R.; Kang, L.; et al. Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy. *Int. J. Cardiol.* 2017, 243, 283–289. [CrossRef]

202. Zymliński, R.; Sierpiński, R.; Metra, M.; Cotter, G.; Sokolski, M.; Siwołowski, P.; Garus, M.; Gajewski, P.; Tryba, J.; Samorek, M.; et al. Elevated plasma endothelin-1 is related to natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. *ESC Heart Fail.* 2020, 7, 3536–3544. [CrossRef] [PubMed]

203. Mo, R.; Yang, Y.; Yu, L.; Tan, H.; Zhu, J. Elevated Plasma Big Endothelin-1 at Admission Is Associated with Poor Short-Term Outcomes in Patients with Acute Decompensated Heart Failure. *Front. Cardiovasc. Med.* 2021, 8, 101. [CrossRef] [PubMed]

204. Gombos, T.; Förhecz, Z.; Pozsonyi, Z.; Wallentin, S.; Papassotiriou, J.; Kunde, J.; Morgenthaler, N.G.; Jánoskuti, L.; Prohászka, Z. Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. *Inflamm. Res.* 2009, 58, 298–305. [CrossRef] [PubMed]

205. Sikkeland, L.I.B.; Dahl, C.P.; Ueland, T.; Andreassen, A.K.; Gude, E.; Edvardsen, T.; Holm, T.; Yndestad, A.; Gullestad, L.; Kongerud, J.; et al. Increased Levels of Inflammatory Cytokines and Endothelin-1 in Alveolar Macrophages from Patients with Chronic Heart Failure. *PLoS ONE* 2012, 7, e36815. [CrossRef] [PubMed]

206. Ward, R.; Ergul, A. Relationship of endothelin-1 and NLRP3 inflammasome activation in HT22 hippocampal cells in diabetes. *Life Sci.* 2016, 159, 97–103. [CrossRef]

207. Dow, C.A.; Templeton, D.L.; Lincenberg, G.M.; Greiner, J.J.; Stauffer, B.L.; DeSouza, C.A. Elevations in C-reactive protein and endothelin-1 system activity in humans. *Life Sci.* 2016, 159, 66–70. [CrossRef]

208. Abbate, A.; Toldo, S.; Marchetti, C.; Kron, J.; Van Tassell, B.W.; Dinarello, C.A. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. *Circ. Res.* 2020, 126, 1260–1280. [CrossRef]

209. Świątkiewicz, I.; Magielski, P.; Kubica, J. C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period. *Int. J. Mol. Sci.* 2021, 22, 3169. [CrossRef]

210. Mylona, P.; Cleland, J.G.F. Update of REACH-1 and MERIT-HF clinical trials in heart failure. *Eur. J. Heart Fail.* 1999, 1, 197–200. [CrossRef]

211. Packer, M.; McMurray, J.J.V.; Krum, H.; Kioiwski, W.; Massie, B.M.; Caspi, A.; Pratt, C.M.; Petrie, M.C.; DeMets, D.; Kobrin, I.; et al. Long-Term Effect of Endothelin Receptor Antagonist with Bosentan on the Morbidity and Mortality of Patients with Severe Chronic Heart Failure. *JACC Heart Fail.* 2017, 5, 317–326. [CrossRef]

212. Anand, I.; McMurray, J.; Cohn, J.N.; Konstan, M.A.; Notter, T.; Quitzau, K.; Ruchitzka, F.; Lüscher, T.F. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial. *Lancet* 2004, 364, 347–354. [CrossRef]

213. Waijer, S.W.; Gansevoort, R.T.; Bakris, G.L.; Correa-Rotter, R.; Hou, F-F.; Kohan, D.E.; Kitzman, D.W.; Makino, H.; McMurray, J.J.V.; Perkovic, V.; et al. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuninuria and Kidney Function. *Clin. J. Am. Soc. Nephrol.* 2021, 16, 1824–1832. [CrossRef] [PubMed]

214. Coletta, A.P.; Cleland, J.G.F. Clinical trials update: Highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology—WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. *Eur. J. Heart Fail.* 2001, 3, 747–750. [CrossRef]
215. Louis, A.; Cleland, J.G.F.; Crabbe, S.; Ford, S.; Thackray, S.; Houghton, T.; Clark, A. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAITE, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. *Eur. J. Heart Fail.* 2001, 3, 381–387. [CrossRef]

216. McMurray, J.J.V.; Teerlink, J.R.; Cotter, G.; Bourge, R.C.; Cleland, J.G.F.; Jondeau, G.; Krum, H.; Metra, M.; O’Connor, C.M.; Parker, J.D.; et al. Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients with Acute Heart Failure. *JAMA* 2007, 298, 2009. [CrossRef]

217. Sutton, G.; Pugh, D.; Dhaun, N. Developments in the Role of Endothelin-1 in Atherosclerosis: A Potential Therapeutic Target? *Am. J. Hypertens.* 2019, 32, 813–815. [CrossRef]

218. Böhm, F.; Pernow, J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. *Cardiovasc. Res.* 2007, 76, 8–18. [CrossRef]

219. Jaguszewski, M.; Osipova, J.; Ghadri, J.-R.; Napp, L.C.; Widera, C.; Franke, J.; Fijalkowski, M.; Nowak, R.; Fijalkowska, M.; Volkmann, I.; et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. *Eur. Heart J.* 2014, 35, 999–1006. [CrossRef]

220. Campia, U.; Tesouro, M.; Di Daniele, N.; Cardillo, C. The vascular endothelin system in obesity and type 2 diabetes: Pathophysiology and therapeutic implications. *Life Sci.* 2014, 118, 149–155. [CrossRef]

221. Fraccarollo, D.; Widder, J.D.; Galuppo, P.; Thum, T.; Tsikas, D.; Hoffmann, M.; Ruetten, H.; Ertl, G.; Bauersachs, J. Improvement of Post-Infarct Ventricular Dysfunction by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction. *J. Mol. Cell. Cardiol.* 2001, 33, 2306–2315. [CrossRef] [PubMed]

222. Pernow, J.; Wang, Q. Endothelin in myocardial ischaemia and reperfusion. *Cardiovasc. Res.* 1997, 33, 518–526. [CrossRef]

223. Ryu, S.M.; Kim, H.J.; Cho, K.R.; Jo, W.-M. Myocardial Protective Effect of Tezosentan, an Endothelin Receptor Antagonist, for Ischemia-Reperfusion Injury in Cardiac Failure Models. *J. Korean Med. Sci.* 2009, 24, 782. [CrossRef] [PubMed]

224. Zhang, J.; Wang, Y.-J.; Wang, X.; Xu, L.; Yang, X.-C.; Zhao, W.-S. PKC-Mediated Endothelin-1 Expression in Endothelial Cell Promotes Macrophage Activation in Atherosogenesis. *Am. J. Hypertens.* 2019, 32, 880–889. [CrossRef]

225. Molet, S.; Furukawa, K.; Maghazachi, A.; Hamid, Q.; Giaid, A. Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells. *J. Allergy Clin. Immunol.* 2000, 105, 333–338. [CrossRef]

226. Li, M.W.; Mian, M.O.R.; Barhoumi, T.; Rehman, A.; Mann, K.; Paradis, P.; Schiffrin, E.L. Endothelin-1 Overexpression Exacerbates Ischemia-Reperfusion Injury in Experimental Heart Failure Models. *J. Mol. Cell. Cardiol.* 2001, 33, 969–981. [CrossRef] [PubMed]

227. Siwik, D.; Migalski, P.; Kubica, J.; Zadourian, A.; DeMaria, A.N.; Taub, P.R. Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. *Int. J. Mol. Sci.* 2020, 21, 807. [CrossRef] [PubMed]

228. Olivier, A.; Girerd, N.; Michel, J.; Ketelslegers, J.; Fay, R.; Vincent, J.; Bramlage, P.; Pitt, B.; Zannad, F.; Rossignol, P. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Ac. *Int. J. Cardiol.* 2017, 241, 344–350. [CrossRef]

229. Øie, E.; Yndestad, A.; Robins, S.P.; Bjørnerheim, R.; Åsberg, A.; Attramadal, H. Early intervention with a potent endothelin-A/endothelin-B receptor antagonist aggravates left ventricular remodeling after myocardial infarction in rats. *Basic Res. Cardiol.* 2002, 97, 239–247. [CrossRef]

230. Solomon, S.D.; Pfeffer, M.A. Renin-Angiotensin System and Cardiac Rupture After Myocardial Infarction. *Circulation* 2002, 106, 2167–2169. [CrossRef]

231. Tsikas, D.; Hoffmann, M.; Ruetten, H.; Ertl, G.; Bauersachs, J. Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction. *Circulation* 2008, 118, 818–827. [CrossRef]

232. Tzanidis, A.; Lim, S.; Hannon, R.D.; See, F.; Ugoni, A.M.; Krum, H. Combined Angiotensin and Endothelin Receptor Blockade Attenuates Abnormal Cardiac Remodeling Post-Myocardial Infarction in the Rat: Possible Role of Transforming Growth Factor β1. *J. Mol. Cell. Cardiol.* 2001, 33, 969–981. [CrossRef] [PubMed]

233. Zhang, C.; Tian, J.; Jiang, L.; Xu, L.; Liu, J.; Zhao, X.; Feng, X.; Wang, D.; Zhang, Y.; Sun, K.; et al. Prognostic Value of Plasma Big Endothelin-1 Level among Patients with Three-Vessel Disease: A Cohort Study. *J. Atheroscler. Thromb.* 2019, 26, 959–969. [CrossRef] [PubMed]

234. Chen, J.; Chen, M.-H.; Guo, Y.-L.; Zhu, C.-G.; Xu, R.-X.; Dong, Q.; Li, J.-J. Plasma Big Endothelin-1 Level and the Severity of New-onset Stable Coronary Artery Disease. *J. Atheroscler. Thromb.* 2015, 22, 126–135. [CrossRef] [PubMed]

235. Verma, S.; Maitland, A.; Weisel, R.D.; Fedak, P.W.M.; Li, S.-H.; Mickie, D.A.G.; Li, R.-K.; Ko, L.; Rao, V. Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: Reversal by means of endothelin antagonism. *J. Thorac. Cardiovasc. Surg.* 2002, 123, 1114–1119. [CrossRef]

236. Tsutamoto, T. Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction. *Eur. Heart J.* 2003, 24, 346–355. [CrossRef]

237. Ihling, C.; Szombathy, T.; Bohrmann, B.; Brockhaus, M.; Schaefer, H.E.; Loeffler, B.M. Coexpression of Endothelin-Converting Enzyme-1 and Endothelin-1 in Different Stages of Human Atherosclerosis. *Circulation* 2001, 104, 864–869. [CrossRef]

238. Ruschitzka, F.; Moehrle, U.; Quasching, T.; Lachat, M.; Noll, G.; Shaw, S.; Yang, Z.; Teupser, D.; Subkowski, T.; Turina, M.I.; et al. Tissue Endothelin-Converting Enzyme Activity Correlates with Cardiovascular Risk Factors in Coronary Artery Disease. *Circulation* 2000, 102, 1086–1092. [CrossRef]
239. Böhm, F.; Jensen, J.; Svane, B.; Settgren, M.; Pernow, J. Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease. Can. J. Physiol. Pharmacol. 2008, 86, 745–751. [CrossRef]

240. Rafnsson, A.; Shemyakin, A.; Pernow, J. Selective endothelin ETA and dual ETA/ETB receptor blockade improve endothelium-dependent vasodilation in patients with type 2 diabetes and coronary artery disease. Life Sci. 2014, 118, 435–439. [CrossRef]

241. Liou, K.; Jepson, N.; Buckley, N.; Chen, V.; Thomas, S.; Russell, E.A.; Ooi, S.-Y. Design and Rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial. Cardiovasc. Drugs Ther. 2016, 30, 169–175. [CrossRef]

242. O’Connor, C.M.; Gattis, W.A.; Adams, K.F.; Hasselblad, V.; Chandler, B.; Frey, A.; Kobrin, I.; Rainisio, M.; Shah, M.R.; Teerlink, J.; et al. Tezosentan in patients with acute heart failure and acute coronary syndromes. J. Am. Coll. Cardiol. 2003, 41, 1452–1457. [CrossRef]

243. Garjani, A.; Wainwright, C.L.; Zeitlin, I.J.; Wilson, C.; Slee, S.-J. Effects of Endothelin-1 and the ETA-Receptor Antagonist, BQ123, on Ischemic Arrhythmias in Anesthetized Rats. J. Cardiovasc. Pharmacol. 1995, 25, 634–642. [CrossRef] [PubMed]

244. De Haro, J.; Bleda, S.; Gonzalez-Hidalgo, C.; Michel, I.; Acín, F. Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial. Am. J. Cardiol. Drugs 2019, 19, 203–209. [CrossRef] [PubMed]

245. De Haro, J.; Bleda, S.; Varela, C.; Esparrza, L.; Michel, I.; Acín, F. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients with Peripheral Arterial Disease. Am. J. Cardiol. 2016, 117, 295–301. [CrossRef] [PubMed]

246. Bartfai, T.; Wang, M.-W. Positive allosteric modulators to peptide GPCRs: A promising class of drugs. Acta Pharmacol. Sin. 2013, 34, 880–885. [CrossRef]

247. Gentry, P.R.; Sexton, P.M.; Christopoulos, A. Novel Allosteric Modulators of G Protein-coupled Receptors *. J. Biol. Chem. 2015, 290, 19478–19488. [CrossRef]

248. Talbodec, A.; Berkane, N.; Blandin, V.; Breitmayer, J.P.; Ferrari, E.; Frelin, C.; Vigne, P. Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol. Pharmacol. 2000, 57, 797–804. [CrossRef]

249. Blandin, V.; Vigne, P.; Breitmayer, J.P.; Frelin, C. Allosteric Inhibition of Endothelin ETA Receptors by 3,5-Dibromosalicylic Acid. Mol. Pharmacol. 2000, 58, 1461–1469. [CrossRef]

250. Wisler, J.W.; Rockman, H.A.; Lefkowitz, R.J. Biased G protein-coupled receptor signaling: Changing the paradigm of drug discovery. Circulation 2018, 137, 2315–2317. [CrossRef]

251. Pang, P.S.; Butler, J.; Collins, S.P.; Cotter, G.; Davison, B.A.; Ezekowitz, J.A.; Filippatos, G.; Levy, P.D.; Metra, M.; Ponikowski, P.; et al. Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: A randomized, double-blind, placebo-controlled, phase IIb, dose ranging trial (BLAST-AHF). Eur. Heart J. 2017, 38, 2364–2373. [CrossRef]

252. Kashihara, T.; Kawagishi, H.; Nakada, T.; Numaga-Tomita, T.; Kadota, S.; Wolf, E.E.; Du, C.K.; Shibuya, Y.; Morimoto, S.; Yamada, M. β-Arrestin–Biased AT1 Agonist TRV027 Causes a Neonatal-Specific Sustained Positive Inotropic Effect without Increasing Heart Rate. JACC Basic Transl. Sci. 2020, 5, 1057–1069. [CrossRef] [PubMed]
263. Teoh, J.P.; Park, K.M.; Wang, Y.; Hu, Q.; Kim, S.; Wu, G.; Huang, S.; Maihle, N.; Kim, I. man Endothelin-1/Endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis. *Cell. Signal.* **2014**, *26*, 2885. [CrossRef] [PubMed]

264. Chaturvedi, M.; Schilling, J.; Beautrait, A.; Bouvier, M.; Benovic, J.L.; Shukla, A.K. Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors. *Trends Biochem. Sci.* **2018**, *43*, 533–546. [CrossRef] [PubMed]

265. Sallum, C.O.; Wilson, J.L.; Rupasinghe, C.; Berg, E.; Yu, J.; Green, D.S.; Taylor, L.; Mierke, D.; Polgar, P. Enhancing and limiting endothelin-1 signaling with a cell-penetrating peptide mimicking the third intracellular loop of the ETB receptor. *Chem. Biol. Drug Des.* **2012**, *80*, 374–381. [CrossRef] [PubMed]

266. Green, D.S.; Rupasinghe, C.; Warburton, R.; Wilson, J.L.; Sallum, C.O.; Taylor, L.; Yatawara, A.; Mierke, D.; Polgar, P.; Hill, N. A Cell Permeable Peptide Targeting the Intracellular Loop 2 of Endothelin B Receptor Reduces Pulmonary Hypertension in a Hypoxic Rat Model. *PLoS ONE* **2013**, *8*, e81309. [CrossRef] [PubMed]

267. Kamath, A.V. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. *Drug Discov. Today Technol.* **2016**, *21–22*, 75–83. [CrossRef] [PubMed]

268. Zhang, C.; Wang, X.; Zhang, H.; Yao, C.; Pan, H.; Guo, Y.; Fan, K.; Jing, S. Therapeutic monoclonal antibody antagonizing endothelin receptor a for pulmonary arterial hypertension. *J. Pharmacol. Exp. Ther.* **2019**, *370*, 54–61. [CrossRef]

269. Dai, Y.; Chen, X.; Song, X.; Chen, X.; Ma, W.; Lin, J.; Wu, H.; Hu, X.; Zhou, Y.; Zhang, H.; et al. Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension. *J. Am. Coll. Cardiol.* **2019**, *73*, 2567–2580. [CrossRef]

270. Dai, Y.; Qiu, Z.; Ma, W.; Li, C.; Chen, X.; Song, X.; Bai, Z.; Shi, D.; Zheng, J.; Pan, G.; et al. Long-Term Effect of a Vaccine Targeting Endothelin-1 Receptor Type A in Pulmonary Arterial Hypertension. *Front. Cardiovasc. Med.* **2021**, *0*, 570. [CrossRef]

271. Jain, A.; Chen, S.; Yong, H.; Chakrabarti, S. Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes. *J. Diabetes Metab. Disord.* **2018**, *17*, 189. [CrossRef]

272. Jain, A.; Mehrotra, V.; Jha, I.; Jain, A. In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes. *J. Diabetes Metab. Disord.* **2019**, *18*, 133–143. [CrossRef] [PubMed]